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 ABSTRACT 
 
 
Infection Models of Intracellular Staphylococcus aureus and the Impact 
of Interleukin 12 on Macrophage Killing Activity 
 
Therwa Hamza 
 
 
Staphylococcus aureus (S. aureus) is the predominant cause of bone and joint 
infections worldwide. These infections may lead to severe bone and joint destruction and 
high mortality. Treatment of bone infections frequently requires long-term hospitalization 
for repeated debridement and prolonged antibiotic treatment. Bacteria including S. aureus, 
however, are often surprisingly successful in overcoming both host defense mechanisms 
and antibiotic treatments resulting in chronic and recurrent bone infections. Indeed, a 
high rate of recurrence or relapse of bone infections has been reported where ~17% of 
infections related to traumatic extremity injuries recur or relapse. One thought is that 
bacteria like S. aureus used to elude host defenses and antibiotic treatments are able to 
“hide” themselves intracellularly within host cells. 
S. aureus has conventionally been considered as an extracellular pathogen, but 
there is growing evidence showing that it can survive intracellularly within host cells. 
Once internalized into host cells, S. aureus may elicit a pro-inflammatory response often 
characterized by the secretion of interleukin 1β (IL-1β), IL-6, IL-12p70 (IL-12), and 
tumor necrosis factor-α (TNF-α) among other cytokines.  Production of pro-inflammatory 
cytokines from infected osteoblasts may disrupt the balance of the immune system 
thereby leading to uncontrolled inflammation and bone destruction. On the other hand, 
IL-12 is released primarily by antigen-presenting cells and acts as a link between innate 
 and acquired immunities by inducing the differentiation of the T helper 1 (Th1) 
phenotype and the release of interferon gamma (IFN-γ) from activated T-cells as well as 
natural killer cells. T-cell-derived IFN-γ is considered crucial to the activation of 
macrophages, the ultimate effector cells in host defense against intracellular infection. 
Studies have shown that both IL-12 and IFN-γ are up-regulated in infection models of 
other bacteria, parasites, and viruses but little is known about how they may contribute to 
the outcome of infection.  
The overall goal of this dissertation is to develop in vitro and in vivo infection 
models of intracellular S. aureus that can aid in understanding the pathogenesis of 
chronic and recurrent infections and to develop effective immunotherapy regimens to 
prevent or treat such infections.  This dissertation starts with an overall literature review 
in Chapter 1 about the bacterium S. aureus, implant-associated infection, and finally IL-
12 as a potential therapeutic agent against infections. Chapter 2 establishes and 
compares two S. aureus infection models utilizing a non-phagocytic cell (osteoblast) and 
a phagocyte (macrophage) and the corresponding cellular responses of each cell type 
upon infection.  In Chapter 3, S. aureus within osteoblasts is used to infect an open 
femur fracture rat model. We have presented the first direct in vivo evidence that 
intracellular S. aureus could be sufficient to induce bone infection in animals and 
intracellular S. aureus could play an important role in the pathogenesis of S. aureus 
infections.  Finally, a potential approach using IL-12 as a therapeutic agent to improve 
macrophage killing activities against intracellular S. aureus is investigated in Chapter 4.     
 
Keywords:  osteomyelitis, Staphylococcus aureus, infection, interleukin 12, cytokine, 
osteoblast, macrophage, rat, intracellular S. aureus. 
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SPECIFIC AIMS 
 
 
For decades, S. aureus has been recognized as one of the most important leading 
cause of hospital- and community-acquired infections worldwide. Controlling S. aureus 
infections, especially chronic and recurrent infections, is a growing clinical challenge, 
and a better understanding of S. aureus pathogenesis and development of new therapeutic 
strategies are of importance. To achieve this long-term goal, my project has three specific 
aims: 
 
1) Establish and compare in vitro S. aureus infection models using phagocytic 
(macrophage) and non-phagocytic cells (osteoblast) 
2) Determine whether intracellular S. aureus can induce bone infection in vivo 
3) Introduce IL-12 as a therapeutic agent to improve the killing efficacy of 
macrophages against intracellular S. aureus 
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CHAPTER 1 
 
 
Literature Review 
 
1.1 Staphylococcus aureus  
 
 
1.1.1. Biology and Virulence Factors 
 
Staphylococcus aureus (S. aureus) is a Gram-positive spherical bacterium, 
between 0.5 to 1.7 μm in diameter, non-motile, facultative anaerobic, catalase and 
coagulase positive that is able to induce ß-haemolysis [1]. Traditionally, S. aureus is 
considered to be an extracellular pathogen [2, 3], but increasing evidence indicates that S. 
aureus might be a facultative intracellular pathogen [4-9]. The species name “aureus”, 
which means “golden” in Latin, is due to the yellow-golden color of the colonies. The 
color is imparted by carotenoid pigments that support the bacteria in the prevention of 
oxidant killing by phagocytes. Approximately, 20-30% of human beings are persistently 
colonized with S. aureus in the nose, skin, mucosa, the axilla region, or gastrointestinal 
tract [10].  
The remarkable success of S. aureus as a pathogen is due to the expression of a 
wide array of virulence factors including a capsule as well as surface-exposed and 
secreted proteins [11, 12]. A schematic representation of S. aureus virulence factors is 
illustrated in Figure 1. Protein A is the hallmark of S. aureus which is able to bind 
immunoglobulins through their fragment crystallizable region (Fc) thereby hampering Fc 
receptor-mediated opsonophagocytosis [13, 14]. Protein A can also induce T-cell-
independent proliferation and apoptosis of B cells [15]. Coagulase is an extracellular 
protein that results in clotting of the blood that might protect the bacterium from  
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Figure 1. Pathogenic factors of Staphylococcus aureus, with structural and secreted 
products both playing roles as virulence factors.  
 
phagocytic uptake by immune cells [16]. The clumping factor A and B bind serum 
fibrin/fibrinogen and reduce the activity of phagocytic immune cells [17]. The collagen-
binding and fibronectin-binding proteins support the adhesion of S. aureus to connective 
tissue, cartilage, and extracellular matrix [18, 19]. Enterotoxin B and toxic-shock-
syndrome-toxin 1 (TSST-1) are bacterial superantigens that bind major histocompatibility 
complex II (MHC II) complexes on antigen-presenting cells leading to 
immunosuppression [20-22]. The α-toxin is the best-characterized and more potent 
cytotoxin of S. aureus. It binds to cell surface receptors and lipid bilayers on host cells 
and forms pores that eventually cause cell death [23, 24]. 
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1.1.2. Intracellular S. aureus 
S. aureus has long been considered an extracellular pathogen [5]. However, many 
studies have demonstrated its remarkable ability to survive and replicate intracellularly 
[25]. The ability of S. aureus to escape host immunity and then establish a cell-niche are 
actually crucial steps in its pathogenesis [3, 5]. 
S. aureus possesses several cell-surface adhesion molecules that facilitate its 
binding to extracellular matrix components. Binding involves a family of adhesins known 
as microbial surface components recognizing adhesive matrix molecules (MSCRAMMs). 
MSCRAMMs recognize proteins such as fibronectin, collagen, and fibrinogen to mediate 
adherence of S. aureus to epithelium, endothelium, bone, and biomaterials coated with 
host proteins [26]. Among all MSCRAMMs, fibronectin-binding proteins (FnBPs) are the 
most critical for adherence and internalization of S. aureus. The schematic representation 
in Figure 2 shows S. aureus attached to α5β1-integrins on the surface of a non-phagocytic 
cells, such as epithelial cells, endothelial cells, or osteoblasts, via fibronectin fibrils that 
are bound to FnBP (attachment). The host cell integrins are associated with myosin 
bound tensins, and by contraction of the myosin, the bacteria are transported toward the 
cell center. The uptake is performed by tensin-mediated actin reorganization [27, 28]. 
Currently, the mechanisms allowing for the intracellular survival of S. aureus 
have not yet been fully understood [5, 29]. In some non-phagocytic cells, S. aureus is 
able to escape from phagolysosomes and multiply in the cytosol. It also leads to the death  
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Figure 2. Schematic diagram of some of the signaling events involved in invasion of 
‘non-professional phagocytic’ host cells by S. aureus. Adapted from Wright and Nair 
(28). 
 
of these cells by apoptosis [30-32]. In contrast, in phagocytic cells, S. aureus seems to 
remain trapped within vacuoles [33, 34] where its multiplication is slowed down but not 
impaired by the acidic pH [35]. S. aureus is also known to produce enzyme degrading 
oxidant species (catalase, hydroperoxide reductase, and superoxide dismutase) [36], 
which may contribute to protecting it intracellularly. 
Within the cell, S. aureus can switch to a phenotype known as small-colony 
variants (SCVs) that provides several advantages for its intracellular survival, among 
which are smaller colony size and reduced growth rate [37-39, 5]. SCVs demonstrate a 
number of characteristics that are different from S. aureus and are linked to interruption 
of electron transport [40]; they also present an altered antibiotic sensitivity [38], being 
most notably resistant to aminoglycosides [41]. SCVs are auxotrophic and can revert to 
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normal growth and morphology in the presence of menadione and hemin, thiamine, or 
CO2-rich culture medium [42]. 
 
1.1.3. Host Immune Response  
Normally, macrophages and other leukocytes in the host eliminate invading 
bacteria by a process called phagocytosis. Bacteria are engulfed into phagosomes and 
eventually fuse with lysosomes forming a phagolysosome where the microorganisms are 
destined for destruction. There, the bacteria are exposed to a number of toxic chemicals 
and enzymatic agents, some of which are reactive oxidative species such as superoxide 
anions and hydrogen peroxide, acidic pH, and degradative proteases. The pathogenicity 
of S. aureus is mainly mediated by a variety of secreted enzymes, adhesins, immuno-
modulating proteins, and the presence of cell wall compounds [43]. Recognition of S. 
aureus components by innate immune cells is the first step of host defense. Toll-like 
receptors (TLRs) are a class of receptors that recognize pathogen-associated molecular 
patterns (PAMPs) such as LPS, peptidoglycan, and lipoprotein [44, 45]. TLRs that are 
involved in the recognition of S. aureus include TLR2 which binds bacterial 
peptidoglycan and TLR9 which binds bacterial CpG DNA. Triggering of TLR signaling 
after pathogen recognition leads to the activation of transcription factors that induce 
transcription of genes coding for various proteins including cytokines and inflammatory 
mediators [46]. This process results in a massive invasion of immune cells to the site of 
infection. Several studies using knockout mice have shown that TLRs play a critical role 
in the innate immune response to Staphylococcal infections as mice deficient in the 
expression of myeloid differentiation factor 88 (MyD88), a cytoplasmic adaptor molecule 
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essential for the signaling of IL-1R/TLR family, are highly susceptible to this pathogen 
[47].  
An effective immune response against S. aureus involves polymorphonuclear cell 
(PMN) recruitment such as neutrophils [48, 49]. The importance of neutrophils in host 
defense against S. aureus infection has been demonstrated by recurrent S. aureus 
infections in patients with chronic granulomatous disease, who have a defect in the 
NADPH oxidase and respiratory burst [48, 50].  
 
1.1.4. Treatment for S. aureus Infections 
Despite increasing knowledge on this bacterium, it is still difficult to prevent or 
effectively treat Staphylococcal infections in many cases. Developing new therapeutic 
strategies (including antibiotic and alternative therapies) as well as prophylaxis strategies, 
which are important for patients before invasive medical procedures, is an essential topic 
in research [51-54]. 
Treatment of S. aureus infections is commonly done using antibiotics, especially 
β-lactams [55]. The hospital-acquired strain of methicillin-resistant S. aureus can be 
susceptible to rifampicin, fusidic acid, and co-trimoxazole but they are rarely used 
because this strain can easily acquire resistance [56]. 
Cationic antimicrobial peptides (CAMPs) such as defensins, cathelicidin, and 
thrombocidins are positively charged (+2 to +7) amphipathic molecules with antibacterial 
properties [57-59]. Produced by the innate immune system, they protect the skin and 
epithelia from bacterial invasion [60]. 
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There is still a problem with the introduction of an efficient vaccine in the 
prevention of infections caused by S. aureus. This can be associated with the fact that, 
throughout its life, a human organism is in contact with this bacterium as many people 
are constant or transient carriers of S. aureus on the mucus of the nasal or oral cavity. 
Earlier, the whole bacterial cell was used as an antigen, but recent research is aimed at 
obtaining antibodies against specific virulence factors such as adhesins, toxins, or 
invasins [61]. 
FnBPs are responsible for adherence of S. aureus to and subsequent 
internalization by phagocytes. Intramuscular application of a recombinant fragment of the 
fibronectin-binding domain (rFnBF), which potentially inhibits the entrance of S. aureus 
to host cells, counteracted the formation of abscesses in guinea pigs. The protective effect 
was dose-dependent and increased the efficacy of preventive treatment if applied 
simultaneously with cefazolin. The efficacy of this method relies on competition in the 
adhesion of exogenic S. aureus rFnBF with FnBP, which causes infection [62]. 
 
 
1.2 Implant-Associated Infections and Osteomyelitis 
 
1.2.1. General Concepts 
Bone turnover is a highly regulated process. New bone is formed by osteoblasts, 
which are cells of mesenchymal lineage derived from osteoprogenitor cells located in the 
periosteum or bone marrow. Osteoblasts form new bone matrix, called osteoid, which is 
later mineralized as osteoblasts mature. When osteoblasts become surrounded by 
mineralized matrix, they become osteocytes. Old or damaged bone is resorbed by 
osteoclasts via a process called bone resorption. Osteoclasts are large multinucleated cells 
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of hematopoietic lineage derived from the fusion of monocytes and macrophages. 
Osteoclasts are activated and recruited to sites of microfracture by factors such as 
macrophage colony stimulating factor (M-CSF) and receptor activator of nuclear factor 
κβ ligand (RANKL). The balance in osteoblast and osteoclast activities is critical for 
healthy bone environment and successful implant procedures. 
Orthopaedic implants are commonly used in treating patients with pain and 
compromised mobility or for fracture fixation. The risk of infection is increased by the 
presence of foreign materials in the body. The most commonly cultured pathogens 
isolated from prosthetic implant-associated infections are S. epidermidis (30 to 43%) and 
S. aureus (12 to 23%), followed by mixed bacterial flora (10 to 11%), streptococci (9 to 
10%), Gram-negative bacilli (3 to 6%), enterococci (3 to 7%), and anaerobes (2 to 4%) 
[63]. Recently, S. aureus SCVs, which have a slower metabolism, do not produce toxins, 
and are more resistant to antibiotics, have been isolated from implant-associated 
infections and represent a risk factor for treatment failure, and persistence and recurrence 
of infection [64]. 
Implant-associated infections occur by bacterial contamination of the surgical site 
during surgery or immediately after, or they result from haematogenous spreading from 
distinct infections in the nose or on the skin. The resulting infection of the bone and soft 
tissue is called osteomyelitis, which is an inflammatory process characterized by massive 
bone destruction, or osteolysis (5). The disease can be acute or chronic with periodic 
recurrence [65, 66]. Chronic osteomyelitis is usually defined as osteomyelitis occurring 
in a patient who cannot be cured by medical means within six weeks [67]. The hallmarks 
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of chronic osteomyelitis include the presence of pus, persisting microorganisms, low-
grade inflammation, and dead bone without a blood supply (sequestra) [68]. 
There are three types of osteomyelitis: haematogenous osteomyelitis which is 
commonly found in children and in elderly patients, osteomyelitis secondary to diabetic 
foot infection, and osteomyelitis caused by local spread from an adjacent infection after 
trauma, surgery, or joint replacement, while the incidence of the latter is the highest [5].  
 
1.2.2. Pathogenesis 
Staphylococci have a strong ability to adhere to plastic surfaces, a fact that has 
been used in basic in vitro assays. However, during colonization on medical devices, the 
additional interaction of MSCRAMMs and host proteins most likely cause a stronger 
attachment (61, 69]. This bacterial colonization forms what is called a biofilm, which is a 
microbial community covered by a thin three-dimensional structure matrix [70, 71]. The 
host immune system responds to foreign bodies with a localized inflammation leading 
first to the formation of a capsule-like membrane of fibrinogen, fibronectin, and collagen 
on the surface [72]. Extracellular proteins such as fibronectin and fibrinogen mediate 
bacterial adhesion to medical devices and host tissue. The localized inflammation causes 
a secondary phenomenon known as “frustrated phagocytosis”, which results from 
granulocyte contact with the foreign body and causes a functional granulocyte defect with 
reduced oxygen burst and chemotaxis in the presence of foreign bodies (Figure 3). This 
process may be partly responsible for the high susceptibility of implants to infections [74]. 
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Figure 3. Pathogenesis of implant-associated infection. Adapted from Biomaterials 
(Biomaterials Science: An Introduction to Materials in Medicine, 2nd edition). 
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1.2.3. Therapy 
The goal of implant-associated infection therapy is a long-term application and 
functional joint and is achieved by elimination of the infection. But, implant-associated 
infections are difficult to treat due to lack of microcirculation, which is crucial for host 
defense and for the delivery of antibiotics. Five treatment approaches utilizing 
appropriate surgical treatment and antimicrobial therapy are available. (I) Long-term 
antimicrobial therapy alone does not eradicate the infection. Additionally, clinical 
symptoms re-appear during or after antimicrobial breaks. (II) Debridement with retention 
of the prosthesis means removal of tissue around a stable implant for patients with an 
early postoperative or acute haematogenous infection (<3 weeks). Furthermore, an agent 
with activity against biofilm bacteria should be available. (III) and (IV) One- or two-stage 
revision includes removal of all devices, debridement, and replacement of a new 
prosthesis during the same procedure or after a period of time, respectively. (V) Finally, 
resection is defined as permanent removal and debridement without replacement [74, 63]. 
 
Surgical intervention as well as antibiotic therapy using cephalosporins and 
penicillins remains the most effective means of treatment for osteomyelitis [75]. However, 
osteomyelitis cases caused by S. aureus are especially chronic in nature and recalcitrant 
to therapy. In addition, the effectiveness of traditional antibacterial agents is becoming 
increasingly limited as the incidence of methicillin-resistant S. aureus (MRSA) has 
increased sharply in recent years. The wide array of virulence factors in S. aureus, 
including secreted products for host damage and immune evasion, coupled with its ability 
to invade and reside inside host cells using cell surface adherence factors, can protect 
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these bacteria from host defense mechanisms and antibiotics which can account for the 
persistence of disease despite what may be considered adequate surgical and antibiotic 
management [76]. 
 
1.3 Interleukin 12: a Key Immunoregulatory Cytokine in Infection Applications 
It is well-established that CD4+ T helper (Th) cells can be divided, besides T 
regulatory and Th17, into two major subsets: Th1 and Th2, based on their patterns of 
cytokine production. Th1 cells mainly secret interleukin 2 (IL-2), IFN-γ, and IL-12, 
whereas Th2 cells secret IL-4, IL-5, and IL-10 [77]. Functionally, Th1 cells 
predominantly promote cell-mediated immunity and help in clearance of intracellular 
pathogens, whereas Th2 cells are responsible for humoral immunity protecting against 
extracellular invaders. The balance between IL-12, favoring Th1 responses, and IL-4, 
favoring Th2 responses, determines the early preference expressed in the immune 
response. 
IL-12 has multiple biological functions; importantly, it bridges the early 
nonspecific innate resistance and subsequent antigen-specific adaptive immunity [78]. IL-
12 was first identified as a product of Epstein-Barr virus (EBV)-transformed human B 
cell lines. IL-12 was previously known as T-cell differentiation factor (TCDF), or natural 
killer cell stimulatory factor (NKSF). IL-12 was used to be the only known heterodimeric 
cytokine, but it is now part of a family consisting of several other members including IL-
23, IL-27, and the recently identified IL-35. These new molecules have been found to 
play distinct cellular and functional roles in Th1 development [79]. 
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1.3.1 IL-12 Molecular Structure 
IL-12 is a key immunoregulatory cytokine [78, 80, 81] with a molecular weight of 
70 kDa; it is composed of two covalently-linked subunits, IL-12p35 (35 kDa) and IL-
12p40 (40 kDa), each of which is expressed on different chromosomes. The sequence of 
the p35 gene is homologous similar to that of IL-6 and granulocyte-colony stimulating 
factor [82]. The sequence of the p40 chain has a homology to the extracellular domain of 
IL-6 receptor (IL-6R) α-chain and the ciliary neurotropic factor [83]. This homology 
explains some of the redundant actions applied by these cytokines. 
Although p35 transcripts are found in many cell types, free p35 is not secreted 
without the p40 subunit. IL-12p40 is produced predominantly by activated monocytes, 
macrophages (MФs), neutrophils, and dendritic cells (DCs). It has been suggested that in 
mice, but not in humans, IL-12p40 homodimers antagonize IL-12p70 activity by binding 
to the β1 subunit of the IL-12 receptor [84-86]. Also, IL-12p40 has been shown to act as 
a chemoattractant for MФs and promotes the migration of stimulated dendritic cells [87]. 
The p40 subunit is associated with several pathogenic inflammatory responses such as 
silicosis, graft rejection, and asthma, but it is also found to be protective in a 
mycobacterial infection model [87]. 
 
1.3.2 IL-12 Receptor and Signaling Pathway 
The biological activities of IL-12 are mediated via binding to a membrane 
receptor complex which is also composed of two subunits: IL-12R β1 and IL-12R β2. 
Both of the subunits are members of the class I cytokine receptor family, which includes 
IL-6, IL-11, and leukocyte inhibitory factor related to glycoprotein gp130 [88, 89]. There  
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Figure 4.  IL-12 signaling pathway. IL-12 activates the Jak/STAT pathway. Following 
binding of IL-12p40 and IL-12p35 to IL-12R β1 and IL-12R β2, respectively, Jak-2 and 
Tyk-2 get transphosphorylated. Phosphorylated IL-12R β2 binds to STAT4 which will 
then dimerize with another STAT4 molecule. STAT4 homodimers translocate to the 
nucleus and promote IFN-γ gene transcription. T-bet is another transcription factor that 
plays a role in Th1 development and IFN-γ production. The IL-12 and IFN-γ produced 
induce the activity and proliferation of MФs, NK cells, and T-cells, which also secrete 
IL-12. Modified from [97]. Reprinted from Cytokine & Growth Factor Rev., 14(5), 
Watford, W.T.; Moriguchi, M.; Morinobu, A.; O'Shea, J.J. The biology of IL-12: 
coordinating innate and adaptive immune responses, 361-368, Copyright (2003), with 
permission from Elsevier. 
 
is a high level of conservation, with a 68% amino acid sequence homology, between 
mouse and human IL-12R β2 proteins, and a 54% sequence identity homology between 
the mouse and human IL-12R β1 [88]. Both receptor chains are required to mediate 
maximal signaling; however, the two chains have independent roles. IL-12R β1 is 
required for high-affinity binding to the IL-12p40 subunit and is associated with the 
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Janus kinase (Jak) family member Tyk-2. The IL-12R β2 chain mediates signal 
transduction via three tyrosine residues that act as a docking site for STAT4; it is 
associated with Jak-2 (Figure 4). IL-12R β2 recognizes either the heterodimer IL-12 or 
IL-12p35 subunit and is expressed, not on naive T-cells, at low levels after T-cell 
receptor stimulation. Expression of this receptor subunit is critically influenced by IL-12 
and type 1 IFNs [81]. The initial expression of functional IL-12Rs is further enhanced 
when IL-12 is present at the time of priming, working as a positive feedback loop 
regulator [90].  
The signaling pathway of IL-12 is described in Figure 4. On binding of IL-12 to 
the IL-12R complex, activation of Jak kinases (Tyk-2 and Jak-2) occurs, leading to 
phosphorylation of the receptor, which becomes a binding site for STAT4 proteins that  
are rapidly recruited to the receptor and phosphorylated on their tyrosine residues by the 
Jak kinases. Tyrosine phosphorylation of STAT4 proteins induces their 
homodimerization and translocation to the nucleus where they bind to specific sequences 
and regulate gene transcription (Figure 4). In Th1 and NK cells, IL-12 mainly induces 
STAT4 activation. In addition, STAT1, STAT3, and STAT5 can also be activated by IL-
12 signaling [89, 91]. Studies have shown that IFN-γ increases the transcription factor T-
bet activity, which was originally shown to be induced in Th1 cells [92]. T-bet response 
to IFN-γ leads to the up-regulation of IL-12R β2 surface expression and allows for Th1 
cell responsiveness to IL-12 [92, 93]. More recent studies showed that T-bet negatively 
regulates GATA-3 expression, the main regulator of Th2 cell axis [94]. In contrast, the 
Th2 cytokine IL-4 reduces IL-12R β2 expression and thus leaves Th2 cells non-
responsive [95]. The opposite effects of IFN-γ and IL-4 on IL-12R β2 expression may 
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contribute to the commitment of Th1/Th2 differentiation. Priming of macrophages with 
IFN-γ increases cellular responsiveness to inflammatory stimuli, including IFN-γ itself, 
which activates direct microbicidal functions including the production of reactive oxygen 
species and TNF-α and promotes the Ag processing and presentation capacities of 
macrophages. Also, IFN-γ plays a role in the regulation of T-cell proliferation and 
activity [96]. 
 
1.3.3 IL-12 Family Members 
The IL-12 family has expanded recently to include members including IL-23, IL-
27, and IL-35. IL-12 and these new family members play critical roles in Th1 cell 
development [80, 98]. Table 1 summarizes the structure and biological properties of these 
major IL-12 family members.  
 
A. Interleukin 23 
IL-23 is a proinflammatory cytokine that is closely related to IL-12 in structure; 
they both share the p40 subunit that is able to build a disulfide bridge complex with the 
p19 subunit to form the biologically active molecule. The p40-p19 complex is mainly 
secreted by activated intestinal antigen presenting cells, such as DCs and monocytes [98]. 
Similar to IL-12 signaling, IL-12R β1is required for high affinity binding to p40, whereas 
IL-23R has a cytoplasmic STAT4 binding domain for signal transduction. However, 
STAT3/STAT4 heterodimers in IL-23 instead of STAT4 homodimers in IL-12 are 
translocated to the nucleus to induce specific gene expression [99].  
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Table 1. The IL-12 cytokine family; structural and biological characteristics. 
 
 
The main role of IL-23 involves the stimulation of Th17 cells to produce IL-17 
[79] and it induces the proliferation of memory T-cells [100]. Unlike IL-12, IL-23 does 
not induce significant production of IFN-γ, and in the absence of IL-23, IFN-γ production 
and Th1 differentiation are still found to be normal [98].  
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B. Interleukin 27 
IL-27 is another heterodimeric cytokine composed of the p28 subunit and the p40-
related protein Epstein-Barr virus-induced gene 3 (EBi3). IL-27 activities are driven via 
one receptor that was described recently with some homology to gp130, known as TCCR 
or WSX-1 [101]. Signaling through TCCR or WSX-1 is required for the early initiation 
of a Th1 response, but not necessary for the maintenance of Th1 responses [101]. The 
signaling pathway initiated by IL-27 activates Jak-1 and Jak-2 molecules. However, only 
STAT1 and STAT3 are critical to IL-27 bioactivities, and STAT3 rather than STAT1 is 
required for IL-27-induced proliferation [102].  
IL-27 is rapidly produced by human phagocytic cells and DCs after their 
activation [101]. IL-27 is involved in early Th1 initiation, is able to induce proliferation 
of naive but not memory T-cells, and can synergize with IL-12 in IFN-γ production [102]. 
 
C. Interleukin 35 
IL-35 was discovered very recently [103]; this heterodimeric cytokine is 
composed of the p35 subunit and the p40-related protein EBi3. IL-35R complex has not 
been characterized yet, but it is possible that it may be composed of the receptors known 
for IL-27 and IL-12, either gp130 or WSX-1 and IL-12R β2. 
Within the CD4+ T-cell population, IL-35 is expressed by resting and activated T 
regulatory cells (Tregs) but not activated T-cells. Loss of IL-35 expression results in 
reduced immune suppression by Tregs. IL-35 appears to function as an anti-inflammatory 
molecule by inhibiting T-cell proliferation. It is suggested that IL-35 can suppress Th17 
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development in vivo [104]; however, further studies are required to fully understand the 
exact mechanism behind these functions. 
 
1.3.4 IL-12 Biological Activities 
IL-12 is produced mainly by DCs, MФs, monocytes, neutrophils, microglia cells, 
and, to a lesser extent, B-cells (Figure 5); human but not murine B cells were found to 
produce IL-12 following CD40 ligation [105]. Non-immune cells such as infected-
keratinocytes and osteoblasts, epithelial, and endothelial cells have also been shown to 
produce some amounts of this cytokine [106, 107]. Pathogen-associated molecular 
patterns such as LPS, teichoic acid, peptidoglycan, and bacterial CpG DNA, can induce 
IL-12 production. The production of IL-12 is regulated by positive and negative feedback 
mechanisms involving Th1 cytokines (e.g. IFN-γ), Th2 cytokines (e.g. IL-10), and type 1 
IFN (Figure 5) [108, 109]. 
IL-12 has multiple biological functions (Table 2) and it bridges innate and adaptive 
immunity. IL-12 induces differentiation of naive CD4+ T-cells to Th1 cells and activates 
NK cells. Upon activation, these cells produce IFN-γ and other type-1 cytokines [110]. 
IL-12 also protects CD4+ Th1 cells from antigen-induced apoptotic death [111]. IL-12 
was found to have synergistic effects with IL-18 in developing Th1 cells, and IL-12 and 
IL-18 reciprocally upregulate each other’s receptors [81]. In addition, IL-12 plays a role 
in T-cell trafficking and migration by inducing functional adhesion molecules such as P- 
and E-selectin ligand expression on Th1 cells but not Th2 cells; therefore, these cells are 
selectively recruited to sites where Th1 immune responses are needed [112]. Studies also 
reported selective expression of CCR5 and CXCR3 when naive T-cells were primed in 
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the presence of IL-12 [110, 113]. Stimulation of MФ-derived IL-12 also plays a major 
role in the induction of resistance in parasitic infestation [114]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.  Summary of the biology of IL-12 [90]. Reprinted by permission from 
Macmillan Publishers Ltd: Nat Rev Immunol., 3, Trinchieri, G. Interleukin-12 and the 
regulation of innate resistance and adaptive immunity, 133-146, Copyright (2003). 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Main immunological functions of IL-12. 
 
 Promote naive CD4+T-cells to differentiate into Th1 
 Enhance the generation and activity of cytotoxic T lymphocytes 
 Induce IFN-γ production by (i) NK cell, T-cell, DC, and MФ, (ii) 
cooperating with B7/CD28 interaction, and (iii) synergizing with 
IL-18 
 Increase MФ antimicrobial activity 
 Prime DC activation to induce more IL-12 production 
 Induce functional adhesion molecule expression on Th1 cells and 
influence T-cell trafficking 
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The biological activity and quantity of IL-12 can be determined using molecular 
approaches. One of the first approaches for quantifying IL-12 was based on IL-12-
induced proliferation of phytoheagglutinin (PHA)-stimulated lymphocytes [115]. 
Peripheral blood mononuclear cells activated with PHA along with IL-2 proliferate in 
response to IL-12. Enzyme-linked immunosorbent assay (ELISA) was also applied to 
quantify specifically IL-12p40 and IL-12p70 [116]. In combination with ELISA, another 
approach, based on the ability of IL-12 to induce IFN-γ secretion from activated T-
lymphoblasts, was developed and has been used to measure the biological activity of IL-
12 [117, 118]. 
 
1.3.5 IL-12 Therapeutic Applications in Infections 
IL-12 holds considerable promise as an immunotherapeutic agent because it plays 
a central role in regulating innate and adaptive immune responses and synergizes with 
several other cytokines for increased immunoregulatory activities. Animal and human 
studies have shown improved outcomes in treating or preventing infections based on the 
mechanisms of IL-12-dependent therapies. 
 
1.3.5.1 Viral Infections 
The role of IL-12 in promoting endogenous protective immune responses to viral 
infections has been attracting more attention with time. Many experimental models have 
been developed to test the potential effects of IL-12 and other immune mediators on 
herpes simplex virus, influenza virus, human immunodeficiency virus (HIV), 
lymphocytic choriomeningitis virus, mouse cytomegalovirus, and many others [119]. 
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A. Herpes simplex virus  
In an in vivo herpes simplex virus-1 (HSV-1) mouse model, sustained expression 
of IL-12 was induced by the virus. This local IL-12 production was considered to cause 
an immunopathological response in the mouse eye environment due to Th1 immunity 
[120]. However, exogenous IL-12 showed a protective role and increased the resistance 
to infection in HSV-1-thermally injured mice, possibly resulting from the activation of 
viral-specific Th1 immunity [121]. Also, IL-12 and IL-18 were shown to play an 
important role in innate immunity against genital HSV-2 infection in a mouse model; the 
protection was mainly mediated by IFN-γ production [122]. 
B. Influenza virus 
CD4+ T-cells are important in controlling influenza A virus infection. CD4+ T-
cells drive the induction and expansion of cytotoxic T lymphocyte (CTL) against such 
viral pathogens. Earlier studies using the influenza virus system as a model showed that 
DCs induced effective CTL response without increasing endogenous IL-12 levels. 
Exogenous application of IL-12 was found to significantly enhance CTL activity [123]. 
Studies also demonstrated a combined effective role of IL-12 and DCs together in 
enhancing CTL immunity to viral infection [123]. The influenza virus vaccination 
effectively protects individuals against serious complications through induction of 
humoral and cellular responses [124]. Interestingly, patients identified with genetic IL-
12/23R β1 or IFN-γR deficiencies were found to develop immune responses to childhood 
vaccination [123]. Also, influenza vaccination could induce humoral immunity and IFN-γ 
production in IL-12/23R β1 deficient patients [125]. These studies may imply that both 
IL-12 and IFN-γ play a significant role in fighting viral infections.  
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C. Human immunodeficiency virus (HIV) 
HIV infection mainly induces Th2 immunity which is unable to clear the viral 
infection most of the time. Glycoprotein gp120 of HIV has been shown to induce IFN-γ 
dependent production of IL-12 in cultured MФs. The use of IL-12 production and Th1 
activation might contribute to decreasing viral load and increasing clearance of the 
infection [126]. However, phase I trials in HIV patients have shown moderate effects 
accompanied by some toxic responses [127].     
 
1.3.5.2 Bacterial Infections 
As a potent inducer of Th1 immune response and an important mediator between 
innate and adaptive immunity, IL-12 has potential clinical uses in treating and preventing 
bacterial infections. 
A. Bone infection 
Osteomyelitis is a bone infection characterized by the presence of necrotic bone 
tissue and increased osteoclast activity. It is commonly caused by Staphylococcus aureus 
(S. aureus), which is traditionally known as an extracellular pathogen; however, it has 
been shown that S. aureus can be internalized and live within a variety of host cells [128, 
129]. Internalization of S. aureus into the host cells could be an important pathogenicity 
factor for escaping the host immune system leading to persistence of infection [130]. It 
was reported that in vitro mouse and human osteoblasts infected with S. aureus express 
high levels of IL-12 [107]; IL-12 and/or IL-23 knockout mice showed an increased 
susceptibility to bacterial, parasitic, and fungal infections [131]. Therefore, IL-12 may 
play a critical role in the downregulation of S. aureus growth in vivo [132]. 
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Figure 6.  Local IL-12 therapy stimulates Th cells to secrete Th1 cytokines [63]. 
Exogenous IL-12 application creates an environment rich in IL-12 around the infection 
site. In such a local environment, newly activated Th cells, responding to the presence of 
bacteria, exit the blood and are influenced to become Th1 cells and secrete more Th1 
cytokines and activate macrophages and NK cells. Activated macrophages will produce 
more IL-12 via a positive feedback; cell-mediated immunity can be promoted to battle 
bacteria thereby leading to the prevention of infection. Reprinted from Biomaterials, 30, 
Li, B.; Jiang, B.; Boyce, B.M.; Lindsey, B.A. Multilayer polypeptide nanoscale coatings 
incorporating IL-12 for the prevention of biomedical device-associated infections, 2552-
2558, Copyright (2009), with permission from Elsevier. 
 
 
More recently, studies have shown that IL-12 may play a significant role in 
preventing osteomyelitis. A decrease in IL-12 production was observed upon pathogen-
mediated ligation of MФ Fcγ or complement receptors [133, 134]. This finding may 
indicate that there are cases in which regulation of IL-12 production can be affected by 
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pathogens. Perhaps down-regulation of IL-12 has the potential of providing pathogens 
with a means of suppressing cell-mediated immunity which would make pathogen 
clearance takes longer and increase the risk of bacterial infections. Meanwhile, IL-12 
production was shown to decrease following trauma or major burn resulting in decreased 
or delayed cell-mediated immune response and decreased resistance to infection [135-
138]. Exogenous application of IL-12, combined with nanotechnology drug delivery 
systems, may have restored the decreased IL-12 level and recovered the host’s cell-
mediated immune response; the combination has been found to be effective in preventing 
open fracture-associated osteomyelitis [139, 140]. The mechanism of protection is related 
to the enhancement of Th1 reactivity and activation of MФs at an early stage following 
surgery (Figure 6) [139]. The activation of MФs may lead to enhanced antigen 
presentation, phagocytosis, Fc receptor expression, and nitric oxide and superoxide 
production [141]. As a result, these changes may substantially increase the ability of 
MФs to kill a wide variety of intracellular and extracellular bacteria and enhance the 
development of long-term immunity to those pathogens [141]. 
 
B. Tuberculosis  
Tuberculosis (TB) is a common and often deadly infectious disease caused by 
mycobacteria including Mycobacterium tuberculosis, Mycobacterium bovis, 
Mycobacterium africanum, Mycobacterium canetti, and others. The chronic nature of 
Mycobacterium tuberculosis (Mtb) infection has led researchers to investigate the host’s 
immunity to respond to and control this disease. Previous reports involving TB infection 
models showed that the development of Th1 cells in response to IL-12 production and 
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subsequent induction of IFN-γ are key players in immunity to TB [142]. Exogenous IL-
12 application was found to result in lower bacterial load and increased incidence of 
survival [143]. DC and Th1 activation and migration to the infected lungs were shown to 
control bacterial growth via IFN-γ–induced activation of phagocytes [144]. This immune 
response, however, may not be solely mediated by IL-12, as the other IL-12 family 
members (IL-23, IL-27, and IL-35) may also participate as well [87]. 
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CHAPTER 2 
 
Staphylococcus aureus Internalization and Associated Biological 
Responses of Osteoblasts and Macrophages 
 
Abstract 
 
The aims of this study were to compare Staphylococcus aureus (S. aureus) 
internalization in a phagocytic cell (i.e. macrophage) to a non-phagocytic cell (i.e. 
osteoblast), and to investigate the cells’ responses upon infection. We found that S. 
aureus could internalize within macrophages and osteoblasts, and upon infection, a 
significantly higher number of live intracellular S. aureus was observed in macrophages 
compared to osteoblasts. The viability of macrophages and osteoblasts both decreased 
with increasing infection time, and macrophages had significantly lower viability during 
2 h infection and significantly higher viability during 8 h infection compared to 
osteoblasts. Moreover, intracellular S. aureus was found to survive within macrophages 
and osteoblasts for approximately 5 and 7 days, respectively. The percentage of S. aureus 
survival within macrophages and osteoblasts decreased with increasing post-infection 
time, and the percentage of S. aureus survival within macrophages was significantly 
lower compared to that within osteoblasts. More importantly, compared to non-infected 
controls, S. aureus infection resulted in (i) significantly increased hydrogen peroxide 
production in macrophages and osteoblasts, (ii) significantly increased superoxide anion 
production in macrophages but not in osteoblasts, (iii) relatively lower alkaline 
phosphatase activity in infected osteoblasts, and (iv) higher phagocytosis activity in 
infected macrophages. 
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1.  Introduction 
Staphylococcus aureus (S. aureus) is one of the primary causes of bone infections 
[1-3]. These infections are often chronic, difficult to eradicate, and cause high morbidity 
rates [4]. S. aureus can gain access deep into bone and soft tissue as a result of severe 
trauma or foreign body implants [5]. Although S. aureus has been traditionally 
considered as an extracellular pathogen, it has been reported by several groups that this 
bacterium can invade and survive within a variety of cells such as neutrophils, 
macrophages, T-lymphocytes, epithelial cells, endothelial cells, fibroblasts, and 
osteoblasts [6-15]. One hypothesis, not yet proven, about chronic and recurrent infections 
is that bacteria internalize into the host cells and such intracellular bacteria may 
potentially lead to their evasion of the host’s immune responses and protection from most 
conventional antibiotics [16]. 
The main role of osteoblasts is to synthesize bone components and induce bone 
matrix mineralization [17]. Osteoblasts are not traditionally considered as part of the 
immune system. However, osteoblasts were recently found to be able to induce 
inflammatory cytokines and chemokines upon S. aureus internalization [18,19]. This 
finding may suggest an important role for osteoblasts in triggering immune responses 
after S. aureus infection. S. aureus can be internalized into osteoblasts and its 
internalization is believed to be mediated by binding of fibronectins on osteoblast 
surfaces, which is connected to the integrin dimer α5β1 molecule and fibronectin-binding 
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proteins on S. aureus surfaces [6]. Protein-ligand interaction leads to S. aureus adhesion 
and invasion by a “zipper-like” mechanism [15]. Eventually, internalized bacteria escape 
into the cytoplasm and may lead to host cell death by apoptosis [20]. In addition, live 
osteoblasts are necessary for S. aureus internalization as formalin-fixed osteoblasts could 
not internalize S. aureus [10,21]. 
The major role of phagocytes, such as macrophages, neutrophils, and dendritic 
cells is to engulf and eliminate a wide variety of invading pathogens. As a result, high 
influxes of such phagocytes are expected at the infection site upon pathogen invasion. For 
instance, a high influx of neutrophils was detected at the infection site of S. aureus bone 
infection [22]. Unfortunately, some pathogens can survive within these phagocytes after 
being phagocytized which may lead to chronic diseases [23,24]. It was reported that S. 
aureus can survive within neutrophils and its survival may have contributed to infection 
persistence as well as dissemination in vivo [7]. Neutrophils are short-lived and are 
unlikely to carry intracellular pathogens for long [25]. Macrophages, however, are long 
lived and may possibly allow surviving pathogens to invade the circulatory system from 
localized infection sites [26] and thereby may be more likely contribute to chronic and 
recurrent infections.  
The aims of this study were to compare S. aureus internalization in a phagocytic 
cell (i.e. macrophage) and a non-phagocytic cell (i.e. osteoblast), and to investigate 
macrophage and osteoblast responses upon S. aureus infection. We hypothesized that S. 
aureus can internalize into macrophages and osteoblasts and survive for at least days, and 
its internalization may lead to changes in macrophage and osteoblast activities. 
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2.  Materials and Methods 
2.2.1. Reagents  
Tryptic soy agar (TSA, w/5% sheep blood) plates, tryptic soy broth (TSB), 
phosphate buffered saline (PBS), fetal bovine serum (FBS), 0.25% trypsin/2.21 mM 
ethylenediaminetetraacetic acid (EDTA) solution, 45% glucose solution, 7.5% sodium 
bicarbonate, sodium pyruvate, and HEPES buffer were all obtained from Fisher Scientific 
(Pittsburgh, PA). Dulbecco's Modified Eagle Media: Nutrient Mixture F-12 
(DMEM/F12) and RPMI-1640 media were purchased from LONZA (Walkersville, MD). 
DiI fluorescent dye, Syto-9, propidium iodide (PI), and 100 U/mL penicillin/100 mg/mL 
streptomycin solution were from Invitrogen (Carlsbad, CA). Gentamicin, Triton X-100, 
cytochalasin D, dimethyl sulfoxide (DMSO), bovine serum albumin (BSA), lysostaphin, 
fluorescein isothiocyanate (FITC), paraformaldehyde, and glutaraldehyde were obtained 
from Sigma (St. Louis, MO). Primary antibody Ab20920 and goat polyclonal to rabbit 
IgG secondary antibody-Cy5 ab6564 were obtained from Abcam (Cambridge, MA). 
Dichlorofluorescin diacetate (H2DCF-DA) and dihydroethidum (DHE) were from Life 
Technologies (Grand Island, NY). 
 
2.2.2. Bacteria 
  S. aureus (ATCC 25923) was obtained from the American Type Culture 
Collection (ATCC, Manassas, VA). A fresh inoculum was prepared by suspending 5 
colonies of S. aureus, grown on a blood agar plate, in 5 mL TSB and incubated at 37oC 
for 18 h. After incubation, the S. aureus inoculum was centrifuged at 3750 rpm for 15 
min at 4oC and washed once with 10 mL PBS to obtain an optical density of 0.80 which 
yields (6-8)×108 colony forming units/mL or CFU/mL. The bacteria pellet was then re-
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suspended in either DMEM/F12 for the infection of osteoblasts or in RPMI-1640 medium 
for the infection of macrophages; both cell culture media were free from 
streptomycin/penicillin and FBS.  
 
2.3. Infection of osteoblasts with S. aureus 
Rat osteoblasts (UMR-106) were obtained from ATCC and grown in full-
supplemented DMEM/F12 medium containing 10% FBS and 1% of 
penicillin/streptomycin solution. In 12-well plates (Fisher Scientific), 3×105 cells/mL 
were seeded and cultured in full-supplemented DMEM/F12 medium for at least 24 h at 
37oC in a 5% CO2 incubator until they reached ~ 80% confluence. Osteoblasts were 
infected and the effects of multiplicity of infection (MOI), which represents S. aureus to 
osteoblast ratio, and infection time on osteoblast infection were investigated:  (1) To 
examine the effect of MOI on osteoblast infection, the osteoblast monolayer was washed 
3 times with PBS and then fresh DMEM/F12 media was added (free from 
streptomycin/penicillin and FBS). Immediately, S. aureus was added at MOIs of 100:1, 
500:1, and 1000:1 and incubated for 2 h. (2) To examine the effect of infection time on 
osteoblast infection, the osteoblast monolayer was washed 3 times with PBS and then 
fresh DMEM/F12 media (free from streptomycin/penicillin and FBS) was added. S. 
aureus was added at an MOI of 500:1 and incubated for different times, i.e. infection 
times, of 0.5, 2, 4, 6, and 8 h. After each time point, the osteoblast monolayer was 
washed 3 times with PBS and treated with 100 μg/mL gentamicin (an antibiotic known 
not to penetrate mammalian cell membranes within a few hours [27,28]) for 2 h at 37oC 
in a 5% CO2 incubator. Osteoblasts were then washed 3 times with PBS and immediately 
lysed with 0.1% Triton X-100 in PBS for 10 min at 37oC; the cell lysates were diluted in 
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PBS and plated on blood agar plates overnight. To determine viability, osteoblasts were 
detached by incubating them at 37oC for 3 min in a 0.25% trypsin/2.21 mM EDTA 
solution; trypsinization was stopped by adding DMEM/F12 medium supplemented with 
10% FBS. Viable osteoblasts were counted using a hemocytometer (Bright-Line Hausser 
Scientific, Horsham, PA) following the trypan-blue exclusion assay which depends on 
cellular membrane integrity; dead cells allow the stain to penetrate while live cells do not. 
 
2.4. Infection of macrophages with S. aureus 
Rat alveolar macrophage cell-line (NR 8383) was obtained from ATCC and 
grown in full-supplemented RPMI-1640 medium containing 10% FBS, 1% 
streptomycin/penicillin, 45% glucose solution, 7.5% sodium bicarbonate, and sodium 
pyruvate. The infection of macrophages with S. aureus was studied at different MOIs and 
infection times. The protocols for infecting macrophages were similar to those of 
infecting osteoblasts as described previously. In brief, 3×105 cells/mL were seeded in 12-
well plates and cultured in full-supplemented RPMI-1640 medium for at least 24 h to 
achieve adherence at 37oC in a 5% CO2 incubator. Cultured macrophages were washed 3 
times with PBS and then infected with S. aureus at different MOIs (100:1, 500:1, and 
1000:1) or infection times (0.5-8 h). Infected macrophages were washed, treated with 
gentamicin, washed again, and then lysed to determine the number of live intracellular S. 
aureus. To determine the viability of macrophages, adherent macrophages were scraped 
using a cell scraper (Fisher Scientific) and combined with floating macrophages from the 
same sample for trypan-blue exclusion assay and hemocytometry. 
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The viability of osteoblasts and macrophages after infection with S. aureus was 
calculated relevant to their control (non-infected) cells according to the following 
equation: 
 
 
 
Note that the total cell numbers in the infected and control samples were the same 
at the beginning of the infection (i.e. infection time = 0 h) but were different at later 
infection time periods (i.e. 0.5-8 h). 
 
2.5. Inhibition of S. aureus internalization in osteoblasts 
Cytochalasin D was re-constituted in 1% DMSO; 3×105 cells/mL were seeded in 
12-well plates and cultured in full-supplemented DMEM/F12 medium to reach ~ 80% 
confluence. The osteoblast monolayer was washed 3 times with PBS and then fresh 
DMEM/F12 media was added (free from streptomycin/penicillin and FBS) together with 
cytochalasin D (0.5, 1, 5, 10, and 20 µg/mL). After culturing for 30 min, S. aureus was 
added at an MOI of 500:1 and further incubated for 2 h. Following treatment with 
gentamicin, infected osteoblasts were lysed and plated to determine the number of live 
intracellular bacteria. 
 
2.6. Survival of S. aureus within osteoblasts or macrophages 
Osteoblasts or macrophages were infected with S. aureus at an MOI of 500:1 for 
2 h, treated with gentamicin, washed, and cultured for up to a week in DMEM/F12 (for 
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osteoblasts) or RPMI-1640 (for macrophages) supplemented with 5% FBS and 5 μg/mL 
lysostaphin; lysostaphin does not penetrate mammalian cell membranes for long time 
periods, e.g. weeks [29-31]. The cell culture media was changed every 3 days. At post-
infection days 0, 1, 3, 5, 6, 7, and/or 8 and 9, independent samples of infected cells were 
washed with PBS, lysed with 0.1% Triton X-100, and plated on blood agar plates to 
determine the number of live intracellular S. aureus. Percentage of live intracellular CFU 
at different times following infection was calculated based on the live intracellular CFU 
immediately after infection (i.e. post-infection day 0). 
 
2.7. Confocal microscopy 
A dual staining approach [32,33] was adopted to visualize intracellular S. aureus. 
Osteoblasts or macrophages were cultured on rounded cover-slips for at least 24 h in full-
supplemented DMEM/F12 or RPMI-1640, respectively. Fresh S. aureus was cultured for 
18 h at 37oC in a 5% CO2 incubator. After washing the bacteria once with PBS, the pellet 
was stained with 100 μg/mL FITC in PBS for 30 min at room temperature prior to 
infection. Excess FITC was removed by washing with PBS and centrifugation at 3750 
rpm for 15 min at 4oC. After infecting with the stained S. aureus for 2 h at an MOI of 
500:1, osteoblasts were trypsinized using a 0.25% trypsin/2.21 mM EDTA solution for 
30 seconds at room temperature to remove adherent extracellular S. aureus; no 
trypsinization was used in the macrophage samples. Osteoblasts or macrophages were 
then fixed with 4% paraformaldehyde in distilled water for 30 min at room temperature. 
Fixed cells were washed 3 times with PBS and blocked with 5% BSA for 1 h at room 
temperature. To further label the extracellular S. aureus, the fixed cells were incubated 
overnight at 4oC with a primary antibody Ab20920S in 5% BSA, washed 3 times with 
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PBS (to remove excess free primary antibody), and then incubated in the dark with a 
secondary antibody-conjugated Cy5 fluorescent dye in 2.5% BSA for 45 min at room 
temperature. After washing the excess secondary antibody with PBS, the cover-slips were 
flipped onto microscopic glass slides and used for image observation; macrophage 
samples were mounted in the presence of 4',6-diamidino-2-phenylindole (DAPI) 
fluorescent dye to visualize the nuclei of macrophages. Slides were visualized using a 
159 Plan-Apochromat 63x/1.40 oil objective on an LSM 510 confocal microscope (Zeiss, 
Jena, Germany). 
To confirm the presence of live intracellular S. aureus and the efficacy of 
gentamicin killing of extracellular S. aureus, osteoblasts were seeded on a rounded cover-
slip overnight. The monolayer was then stained with DiI fluorescent dye for 20 min at 
37oC in the dark. The monolayer was washed once with PBS and infected with Syto-9 
labeled S. aureus as aforementioned. After gentamicin treatment, infected osteoblasts 
were washed 3 times with HEPES buffer and PI stain was added for 15 min at room 
temperature in the dark. Immediately after washing off the excess PI, the slides were 
examined under the LSM 510 confocal microscope and images of Z-stack sections were 
taken to confirm the live intracellular S. aureus. Z-stack sections were generated and the 
X-Y planes showed that all live (green) S. aureus was inside the osteoblasts. 
 
2.8. Transmission electron microscopy (TEM)  
Osteoblasts were infected with S. aureus at an MOI of 500:1 for 2 h, washed once 
with PBS, and detached using trypsin-EDTA. Osteoblasts were then collected by 
centrifugation at 1200 rpm at 4oC for 7 min, and the pellet was washed twice with PBS 
then fixed with 2% paraformaldehyde and 4% glutaraldehyde mixed with 0.075 M PBS 
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for 30 min at room temperature. The fixed cell mass was collected in 1.5 mL Eppendorf 
tubes. The cell pellet was washed 3 times with PBS, post-fixed in 1% osmium tetroxide 
for 2 h at room temperature, washed 3 times with PBS, treated with aqueous 1% tannic 
acid for 1 h at room temperature, and then dehydrated in a gradient ethanol series. The 
cells were embedded in pure LR white resin solution and polymerized at 60°C for 24-
48 h. Thin (0.1 μm) sections were cut and placed on nickel grids, stained with 2% uranyl 
acetate and lead citrate, and viewed using TEM (JEOL, Peabody, MA). 
 
2.9. Reactive oxygen species production 
Osteoblasts and macrophages were infected with S. aureus at an MOI of 500:1. At 
pre-determined time points (0.5, 1, and 2 h), samples of infected osteoblasts or 
macrophages were taken, washed once with PBS, and then incubated with H2DCF-DA 
or DHE at 37 C for 1 h in the dark; separate samples were used for the staining of 
H2DCF-DA and DHE. Non-infected osteoblasts and macrophages were used as controls 
and were treated the same as the infected cells except no S. aureus was added. Viable 
cells of infected and control samples at the pre-determined time points were obtained 
using hemocytometry and were used to analyze the final fluorescent data. The 
fluorescence intensity was measured using a fluorescent microplate reader (BioTek 
Instrument, Inc., Winooski, VT) at 492 nm/520 nm for 2',7'-dichlorofluorescein (DCF), 
converted intracellularly from H2DCF-DA, and 492 nm/620 nm for DHE. H2DCF-DA 
and DHE are commonly used to stain intracellular hydrogen peroxide (H2O2) and 
superoxide anion (O.2
-), respectively [34]. The acetate groups of H2DCF-DA are cleaved 
by intracellular esterases and oxidation and convert to highly fluorescent DCF. 
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2.10. Osteoblast alkaline phosphatase (ALP) activity 
Osteoblasts were cultured in 12-well plates at a density of 5×104 cells/mL, 
infected at an MOI of 500:1 for 2 h following the aforementioned infection protocol. 
Non-infected (control) and infected osteoblasts were cultured in DMEM/F12 
supplemented with 5% FBS and 5 μg/mL lysostaphin solution for a week; media was 
changed every 3 days. On post-infection days 1, 4, and 7, osteoblast monolayers were 
washed with PBS once and the ALP activity was determined using an ALP assay kit 
(Abcam) and expressed as Unit/mL. 
 
2.11. Macrophage phagocytosis assay 
Macrophage phagocytosis (ingestion) activity was tested by measuring the uptake 
of FITC-labeled S. aureus by non-infected (control) macrophages and macrophages 
infected with S. aureus (unlabeled) at an MOI of 500:1 for 2 h. After incubating 5×105 
cells/mL non-infected (control) and infected macrophages separately with FITC-labeled S. 
aureus at 10:1 MOI for 2 h, macrophages (infected and non-infected) were treated with 
100 μg/mL gentamicin for 2 h at 37 C in a 5% CO2 incubator. Macrophages were then 
scraped and collected for flow cytometry analysis using BD-FACS Calibur (BD, Franklin 
Lakes, NJ); 10,000 events were collected. Data were acquired in logarithmic mode for the 
forward scatter (FSC), side scatter (SSC), and green fluorescence channel FL-1H (i.e. 
FITC). Control macrophages were subjected to the same experimental protocols as the 
infected cells but without infection with S. aureus. The percentage of macrophages with 
FITC fluorescent intensity corresponds to the ingestion activity of macrophages.  
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2.12. Statistical analysis 
Statistical analyses were performed using JMP Statistical Visualization Software 
(SAS Institute, Cary, NC). Experiments were repeated at least twice on separate days to 
verify reproducibility. All data were expressed as mean ± SD and analyzed using one-
way analysis of variance (ANOVA). Statistical significance was set at p<0.05. 
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3.  Results 
3.1. Characterization of S. aureus infection of osteoblasts and macrophages 
After incubating with S. aureus for 2 h at an MOI of 100:1 to 1000:1, osteoblasts 
and macrophages were both found to be infected. However, significantly higher (~ 2 
orders) numbers of intracellular S. aureus were found within macrophages compared to 
osteoblasts (Figure 2A); the intracellular CFUs for infected macrophages and osteoblasts 
were approximately 3.5×106 and 3.1×104 CFU/(105 cells), respectively. No significant 
differences were observed in the same cell type at the various MOIs studied (i.e. 100:1, 
500:1, and 1000:1). By contrast, significantly lower viability was observed in 
macrophages compared to osteoblasts at 2 h infection; the viability of macrophages and 
osteoblasts were 62-78% and 90-95%, respectively (Figure 2B). No significant 
differences in viability for the same cell type at the MOIs investigated (i.e. 100:1, 500:1, 
and 1000:1) were noticed following the 2 h infection.  
 
At an MOI of 500:1, the number of intracellular S. aureus for both macrophages 
and osteoblasts increased with increasing infection time and reached a plateau at 2 h, at 
which point the intracellular CFUs for macrophages and osteoblasts were 5.0×106  and 
3.9×104   CFU/(105 cells), respectively (Figure 2C). At the infection times of 2-8 h, the 
intracellular CFUs for macrophages were significantly (about 2 orders) higher than those 
of osteoblasts. At an MOI of 500:1, the viability of macrophages and osteoblasts 
decreased approximately linearly with increasing infection time. The viability of 
macrophages at infection times of 2, 4, 6, and 8 h was significantly lower than that of 
both macrophage control and at infection time of 0.5 h. The viability of osteoblasts at  
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Figure 2 (A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 (B) 
 
Figure 2.  S. aureus infection of osteoblasts and macrophages. (A) Live intracellular S. 
aureus and (B) viability of osteoblasts and macrophages at different MOIs (100:1, 500:1, 
and 1000:1) for 2 h. *p<0.05 and **p<0.001 compared to osteoblasts at the same MOI. 
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infection times of 4, 6, and 8 h was significantly lower than that of both osteoblast control 
and at infection time of 0.5 h (Figure 2D). In addition, the viability of macrophages was 
significantly lower at 2 h infection but significantly higher at 8 h infection compared to 
osteoblasts at corresponding infection time periods (Figure 2D). 
The S. aureus infection of osteoblasts was also found to be significantly inhibited 
by the addition of cytochalasin D. The intracellular CFUs of S. aureus decreased 
significantly with increasing cytochalasin D at the dose range studied (0.5-20 μg/mL), 
reaching 50% inhibition at 20 μg/mL (Figure 2E). Relatively higher cytochalasin D doses 
of 10 and 20 μg/mL also led to significantly lower intracellular CFUs of S. aureus 
compared to the doses of 0.5, 1, and 5 μg/mL (Figure 2E). 
 
 
 
 
 
 
 
 
 
Figure 2 (C). S. aureus infection of osteoblasts and macrophages. Live intracellular S. 
aureus and at an MOI of 500:1 for various infection times. **p<0.001 compared to 
osteoblasts at the same infection time.  
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Figure 2 (D). S. aureus infection of osteoblasts and macrophages. Viability of osteoblasts 
and macrophages at an MOI of 500:1 for various infection times. &p<0.01 compared to 
macrophages at infection times 0 and 0.5 h, ^p<0.01 compared to osteoblasts at the same 
infection times, and #p<0.05 compared to osteoblasts at infection times 0 and 0.5 h 
 
 
 
 
 
 
 
 
 
 
Figure 2 (E). S. aureus infection of osteoblasts and macrophages. Effect of cytochalasin 
D on S. aureus internalization in osteoblasts. **p<0.001 compared to the controls and 
^^
p<0.001 compared to 0.5, 1, and 5 µg/mL.  
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S. aureus was found to be able to survive within macrophages and osteoblasts for 
approximately a week; live intracellular S. aureus was found in macrophages and 
osteoblasts for 5 and 7 days, respectively (Figure 3). The percentage of live intracellular S. 
aureus for both macrophages and osteoblasts decreased continuously with increasing 
culturing time after infection, and significantly reduced survival of S. aureus was found 
in macrophages compared to osteoblasts at the same post-infection time period (Figure 3).  
In addition, no differences in osteoblast proliferation were observed between infected and 
non-infected osteoblasts within one week post-infection (data not shown).  
 
 
 
 
 
 
 
 
 
 
Figure 3.  Survival of intracellular S. aureus within osteoblasts and macrophages after 
infection at an MOI of 500:1 for 2 h. **p<0.001 compared to osteoblasts at the same post-
infection time. 
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Confocal microscopy and TEM images confirmed that S. aureus was internalized 
and could survive within macrophages and osteoblasts (Figure 4). Meanwhile, 
substantially more (likely two orders) S. aureus was internalized (not necessarily alive) 
by macrophages compared to osteoblasts (Figure 4A and B). Confocal microscopy 
imaging also found that all live S. aureus was inside the osteoblasts and there were no 
live S. aureus on the surface of the osteoblasts after gentamicin treatment (Figure 4C). 
The internalization of S. aureus within osteoblasts was found to be non-uniform as some 
osteoblasts had multiple S. aureus bacteria while others had none (Figure 4D). 
 
 
 
 
 
 
 
                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          
Figure 4 (A) 
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Figure 4 (B) 
 
 
Figure 4.  Visualization of intracellular S. aureus within (A) macrophages and (B) 
osteoblasts. Osteoblasts and macrophages were infected with S. aureus at an MOI of 
500:1 for 2 h. (A and B) S. aureus was stained with FITC before infection. Infected 
osteoblasts and macrophages were fixed, blocked, stained first with primary antibody to S. 
aureus surface protein A, and then secondary antibody conjugated to Cy-5. The nuclei of 
the macrophages were additionally stained with DAPI. Visualized at (I) 488 nm, (II) 633 
nm, and (III) 405 nm. (IV) Merged images of (I), (II), and (III). As a result, intracellular S. 
aureus is shown in green (FITC) and extracellular S. aureus is co-localized with both red 
(Cy-5) and green (FITC).                   
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Figure 4.  Visualization of intracellular S. aureus within osteoblasts. (C) Z-stack sections 
were used to confirm that all live S. aureus was inside osteoblasts as determined by the 
X-Y planes. Live S. aureus are green (Syto 9) and dead S. aureus are red (PI). 
Osteoblasts were infected with Syto 9-labeled S. aureus, then extracellular bacteria were 
killed with gentamicin and washed. Osteoblasts were detached from the wells and stained 
with PI. Approximately 20 cells (randomly selected) were examined. 
 
 
 
3.2. Biological responses of osteoblasts and macrophages upon S. aureus infection 
Significantly higher H2O2 levels were observed at 0.5 and 1 h in infected 
osteoblasts compared to non-infected osteoblasts, i.e. control (Figure 5A). Significantly 
higher H2O2 levels were also observed following a 1 h infection in macrophages 
compared to non-infected control (Figure 5A). No significant changes in O.2
- production 
in osteoblasts were observed at the infection time periods studied (i.e. 0.5, 1, and 2 h), 
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while significantly higher O.2
- levels were found in macrophages at 0.5 and 1 h infection 
(Figure 5B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 (D).  Visualization of intracellular S. aureus within osteoblasts. Confirmation of 
intracellular S. aureus within osteoblasts using TEM.  
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Figure 5 (A) 
 
 
 
 
 
 
 
 
 
Figure 5 (B) 
 
Figure 5.  Cellular and molecular responses of osteoblasts and macrophages infected 
with S. aureus at an MOI of 500:1 for 2 h. (A) DCF fluorescence intensity as an indicator 
of H2O2 production by non-infected controls and S. aureus-infected osteoblasts and 
macrophages. (B) DHE fluorescence intensity as an indicator of O.2
- production by non-
infected controls and S. aureus-infected osteoblasts and macrophages. *p<0.01, **p<0.001, 
and ***p<0.0001 compared to control. 
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No significant changes in ALP enzyme activity were found between infected and 
non-infected osteoblasts at post-infection days 1, 4, and 7, although the ALP activity was 
lower for the infected cells at days 4 and 7 (Figure 5C). The macrophage phagocytosis 
activity studies showed that the ability to ingest bacteria was much higher for infected 
macrophages (83%) compared to non-infected ones (44%) (Figure 5D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 (C).  Cellular and molecular responses of osteoblasts and macrophages infected 
with S. aureus at an MOI of 500:1 for 2 h. Osteoblast ALP activity measured at post-
infection days 1, 4, and 7. 
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Figure 5 (D) 
 
 
 
 
Figure 5 (D). Cellular and molecular responses of osteoblasts and macrophages infected 
with S. aureus at an MOI of 500:1 for 2 h. Macrophage phagocytosis activity (ingestion). 
Light gray area: control macrophages without incubation with S. aureus; dark gray area: 
non-infected macrophages; black area: infected macrophages. *p<0.01, **p<0.001, and 
***
p<0.0001 compared to control. 
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4.  Discussion 
S. aureus has been traditionally considered as an extracellular pathogen; however, 
it has been shown to invade and survive within both non-phagocytic and phagocytic cells. 
By nature, the internalization and survival of S. aureus within non-phagocytic and 
phagocytic cells would be expected to be different, and may play significantly different 
roles in related diseases. To our knowledge, there are no reports comparing S. aureus 
infection of a non-phagocytic cell with a phagocytic cell. Therefore, the main goal of the 
present study was to compare the internalization behavior and related biological 
responses of S. aureus in a non-phagocytic cell (i.e. osteoblast) and a phagocytic cell (i.e. 
macrophage). Our findings may contribute to the understanding of the pathogenesis of 
many chronic and recurrent infections. 
First, we showed that S. aureus can be internalized by both osteoblasts and 
macrophages. The infection of osteoblasts and macrophages was observed as early as 0.5 
h at an MOI of 500:1; the corresponding live intracellular CFUs of S. aureus for 
osteoblasts and macrophages at 0.5 h were 1.4×103 and 7.2×104 CFU/(105 cells), 
respectively (Figure 2C). With increasing infection time, the intracellular CFUs of both 
osteoblasts and macrophages increased significantly from 0.5 h to 2 h followed by a 
plateau from 2 h to 8 h (Figure 2C). Since macrophages are supposed to engulf and 
eliminate pathogens on contact, it was not surprising to find that, at the same infection 
conditions (i.e. MOI of 500:1 for 2 h), significantly more (approximately two orders) S. 
aureus (live and dead) was phagocytized by macrophages compared to those internalized 
by osteoblasts (Figure 4A and B). Similarly, significantly more live intracellular S. 
aureus was seen in macrophages compared to osteoblasts during infection times 2-8 h 
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(Figure 2A and C). Macrophages had significantly lower viability at a shorter infection 
time period (i.e. 2 h) and significantly higher survival at a longer infection time (i.e. 8 h) 
compared to infected osteoblasts (Figure 2D). In addition, it is possible that the 
accumulation of toxins produced by S. aureus [35,36] and the significantly higher levels 
of H2O2 in infected osteoblasts and macrophages and O
.
2
- in infected macrophages 
(Figure 5A and B) affected the viability of macrophages and osteoblasts; both decreased 
(almost linearly) with increasing infection time (Figure 2D). It also seems that actin 
cytoskeleton formation plays a major role in S. aureus internalization into osteoblasts 
since cytochalasin D, an inhibitor that disrupts actin filament polymerization, could lead 
to up to 50% inhibition of S. aureus internalization (Figure 2E). This finding was 
consistent with other studies [21,37] where actin filament was determined to play a 
dominant role in S. aureus internalization.  
Note that our data (Figure 4C) confirmed that gentamicin treatment was effective 
in eliminating extracellular S. aureus and the post-infection CFU was indeed from live 
intracellular S. aureus. Gentamicin treatment is commonly used to eliminate extracellular 
bacteria [19,37], but such a procedure lacks direct confirmation of live intracellular 
bacteria. In this study, the dual staining approach combined with confocal microscopy 
presented direct evidence that no live extracellular S. aureus was observed after the 
gentamicin treatment (Figure 4C). 
Next, we found that S. aureus could survive intracellularly for up to 5 and 7 days, 
respectively, within macrophages and osteoblasts (Figure 3). As a phagocytic cell, 
macrophages were obviously more effective than osteoblasts at not only phagocytizing 
but also destroying the intracellular bacteria. This observation was supported by the 
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findings that S. aureus infection not only significantly increased the H2O2 levels in 
macrophages at 1 h infection but also significantly increased the O.2
- levels in 
macrophages at infection times of 0.5 and 1 h (Figure 5A and B). In contrast, S. aureus 
infection induced significantly higher levels of H2O2 in osteoblasts at 0.5 and 1 h 
infection but did not induce significant changes in O.2
- levels in osteoblasts (Figure 5A 
and B). As a result, significantly higher intracellular CFUs were found in macrophages 
immediately after infection (Figure 2C) while significantly less intracellular S. aureus 
survived in the following days after infection (Figure 3). Complete elimination of the 
intracellular bacteria by macrophages was found at an earlier time period (day 5 vs. day 
7) compared to osteoblasts (Figure 3). Survival of S. aureus within host cells was also 
reported in other cell types. For instance, S. aureus was found to survive within human 
lung epithelial cells for up to 2 weeks [38], persisting in macrophage vacuoles for 3-4 
days before escaping into the cytoplasm and causing macrophage lysis [6], and remaining 
viable for up to 5 days within HT-29 and Caco-2 enterocytes [39]. It was proposed that, 
once inside osteoblasts, macrophages, or other cells, S. aureus may undergo phenotypic 
switching to small colony variants (SCVs), which are associated with increased 
anchoring of fibronectin-binding proteins and clumping factors on the bacterial surface 
[40,41]. These proteins may function as substrates for bacterial enzymes needed to evade 
phagocytic oxidative killing [6,42] thereby contributing to the intracellular survival of S. 
aureus. Moreover, S. aureus produces catalase, which catalyzes the decomposition of 
H2O2, thereby protecting itself inside host cells such as macrophages [43]. It was believed 
that the phenotypic switching of S. aureus may make the bacteria more resistant to 
antibiotics [16,44]. The survival of S. aureus within cells like macrophages and 
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osteoblasts and the possible phenotypic switching of S. aureus may explain why 
antibiotics have so often failed to cure Staphylococcal infections [2,16,41]. Future studies 
may focus on investigation of the possible changes that occur to S. aureus after 
internalization into osteoblasts and macrophages.  
Lastly, we found that S. aureus infection resulted in significantly increased levels 
of H2O2 in infected osteoblasts at infection times of 0.5 and 1 h and in infected 
macrophages at infection time of 1 h (Figure 5A). The O.2
- levels in infected 
macrophages significantly increased at infection times of 0.5 and 1 h (Figure 5B). The 
increase in reactive oxygen species indicates that S. aureus internalization induced 
significant stress in osteoblasts and macrophages which would produce such chemicals to 
eliminate the invading pathogens. S. aureus infection also resulted in much higher 
phagocytosis activity of macrophages (Figure 5D) and relatively lower (although not 
significant) ALP activity of osteoblasts at days 4 and 7 after infection (Figure 5C). This 
effect could be associated with the significant increase in H2O2 and O
.
2
- levels. It is 
noteworthy that, besides the significant changes in reactive oxygen species, S. aureus 
internalization in osteoblasts also led to significantly higher production of IL-6 and IL-12 
[19,45], macrophage chemoattractant protein 1, IL-8, IP-10, RANTES [19,45], and 
RANK-L and prostaglandin E2 (two important molecules that can promote 
osteoclasteogenesis and bone resorption) [46]. 
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5.  Conclusions 
In this study, we intended to compare two infection models of osteoblast-S. 
aureus and macrophage-S. aureus. We found that S. aureus could internalize in 
macrophages and osteoblasts, that the internalization increased substantially with 
increasing infection time from 0.5 h to 2 h, and that the internalization process may have 
been primarily mediated by osteoblast actin cytoskeleton formation. Internalized S. 
aureus could survive within macrophages and osteoblasts for up to 5 and 7 days, 
respectively. Our confocal and transmission electron microscopy observations clearly 
confirmed the presence of live S. aureus within osteoblasts and macrophages and that 
gentamicin treatment was effective in killing extracellular S. aureus; no live extracellular 
S. aureus was detected after gentamicin treatment. Transmission electron microscopy 
also demonstrated that the internalization in osteoblasts was not uniform; some 
osteoblasts had several bacteria while others had none. Confocal microscopy observation 
showed that significantly more S. aureus was internalized in macrophages compared to 
osteoblasts. Similarly, a significantly higher (two orders) level of live intracellular S. 
aureus was detected in macrophages compared to osteoblasts at 2 h infection among 
different MOIs (i.e. 100:1, 500:1, and 1000:1) and at different infection times (2-8 h) at 
an MOI of 500:1. However, the percentage of S. aureus survival after infection was 
significantly lower in macrophages compared to osteoblasts at post-infection days 1-6. 
The viability of macrophages and osteoblasts both decreased with increasing infection 
time between 0-8 h and macrophages had relatively lower viability at shorter infection 
time periods (i.e. 0.5-4 h; significant at 2 h) and higher viability at longer infection time 
periods (i.e. 6-8 h; significant at 8 h) compared to osteoblasts.  
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S. aureus infection also led to noticeable changes in macrophages and osteoblasts. 
Significantly increased H2O2 production was observed in osteoblast-S. aureus infection at 
0.5 and 1 h and in macrophage-S. aureus infection at 1 h. At 0.5 and 1 h infection, 
significantly increased superoxide anion production was found in macrophages. Infected 
osteoblasts had relatively lower ALP activity at post-infection days 4 and 7 and infected 
macrophages had higher phagocytosis activity compared to non-infected cells. Since 
chronic and recurrent bone infections have been frequently reported, are often associated 
with S. aureus and may be related to the intracellular persistence of S. aureus within host 
cells (e.g. osteoblasts, macrophages), the present study helps to better elucidate S. aureus 
internalization and its effects on host cells. This study may assist in evaluating the 
pathogenesis of chronic and recurrent infections and developing new therapeutic 
strategies against intracellular bacteria and diseases. 
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CHAPTER 3 
 
Intracellular Staphylococcus aureus Causes Bone Infection: In vivo 
Evidence 
 
 
Abstract 
 
Chronic and recurrent bone infections occur frequently but have not been fully 
explained. Staphylococcus aureus (S. aureus) is often found in these chronic and 
recurrent infections and may be responsible for such infections. One possible reason is 
that S. aureus can internalize and survive within host cells and by doing so, S. aureus can 
evade both host defense mechanisms and most conventional antibiotic treatments. 
However, no in vivo evidence in the literature has shown that S. aureus internalized into 
host cells is directly responsible for infections. In this study, we hypothesized that intra-
cellular S. aureus could induce infections in vivo. Osteoblasts were infected with S. 
aureus and, after eliminating extra-cellular S. aureus, the osteoblasts were inoculated into 
an open femur fracture rat model. Bacterial cultures and radiographic observations 
confirmed local bone infections in animals inoculated with intra-cellular S. aureus within 
osteoblasts alone at post-operative day 21. We present the first direct in vivo evidence 
that intra-cellular S. aureus could be sufficient to induce bone infection in animals; we 
found that intra-cellular S. aureus inoculation of as low as 102 colony forming units could 
induce severe bone infections. Our data may suggest that intra-cellular S. aureus can 
“hide” in host cells during symptom-free periods and, under certain conditions, they may 
escape and lead to infection recurrence. Intra-cellular S. aureus therefore could play an 
important role in the pathogenesis of S. aureus infections, especially those chronic and 
44%               83% 
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recurrent infections in which disease episodes may be separated by weeks, months, or 
even years. 
 
Keywords:  Chronic infection, infection recurrence, intra-cellular pathogen, 
Staphylococcus aureus, in vivo, co-culture 
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Introduction 
 
Bone infection or osteomyelitis is a significant clinical problem which can lead to 
prolonged hospitalization, sepsis, poor functional outcome, and even death [1-4]. Patients 
with traumatic open fractures have a high risk of infection (5-33%) due to microbial 
contamination and soft tissue damage [5], and such infections are often hard to eradicate, 
long-lasting (i.e. chronic), and recurrent [6]. For instance, over a million Americans are 
hospitalized every year for bone fractures [7]; such injuries are increasingly common 
because of increased survivability of high energy trauma in civilian settings as well as in 
combat activities. Treatment of bone infections, particularly chronic and recurrent 
infections, frequently requires long-term hospitalization for repeated debridement and 
prolonged parenteral antibiotic therapy. Bacteria including Staphylococcus aureus (S. 
aureus), however, are often surprisingly successful in overcoming both host defense 
mechanisms and antibiotic treatments resulting in chronic and recurrent bone infections; 
indeed, a high rate of recurrence or relapse of bone infections was reported where ~17% 
of infections related to traumatic extremity injuries recur or relapse [8, 9]. It is thought 
that bacteria may elude host defenses and antibiotics and can “hide” themselves 
intracellularly within host cells [10]. Unfortunately, evidence to support the hypothesis 
that intracellular bacteria are responsible for or contribute to bone infections in animals or 
humans is sparse or does not exist.  
A wide range of bacterial species have been isolated related to bone infections. 
The pathogen S. aureus is the most common causative agent of bone infections, 
contributing to approximately 80% of all human disease cases [11]. S. aureus is a normal 
flora that colonizes the skin, skin glands, and mucous membranes, specifically in the nose 
74 
 
of healthy individuals. S. aureus expresses a large number of cell surface proteins (i.e. 
adhesins) of the microbial surface components recognizing adhesive matrix molecules or 
MSCRAMMs [12, 13] through which it can colonize the bone matrix and adhere to bone 
cell surfaces. S. aureus, while generally considered an extracellular pathogen, is one such 
bacterium that has the ability to invade and live within different cell types, including 
phagocytic and non-phagoytic cells (reviewed in reference 14). By “hiding” inside the 
host cells, S. aureus may escape from host defenses and most antibiotic treatments and 
may be responsible for chronic and recurrent bone infections. 
To our knowledge, there is no definitive in vivo evidence showing that S. aureus 
“hiding” intracellularly is directly responsible for or contributes to infections. The 
objective of this study was to determine whether intracellular S. aureus can induce bone 
infections in a rat model.  By pre-infecting osteoblasts in vitro with S. aureus, killing 
extracellular bacteria with gentamicin, and inoculating infected osteoblasts into an open 
femur fracture rat model, we examined the bone infections in rats induced by intracellular 
S. aureus. 
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Materials and Methods 
Reagents 
Dulbecco’s modified Eagle’s medium-F 12 (DMEM-F 12) and phosphate 
buffered saline (PBS) were purchased from Lonza (Walkersville, MD). Tryptic soy broth 
(TSB) and tryptic soy agar (TSA w/5% sheep blood) plates were from Fisher Scientific 
(Pittsburgh, PA).  Fetal bovine serum (FBS), 0.25% trypsin-ethylenediaminetetraacetic 
acid (EDTA), and 100 U/mL penicillin/100 mg/mL streptomycin were obtained from 
Invitrogen (Carlsbad, CA). Triton X-100 was from Sigma (St. Louis, MO). S. aureus 
(American Type Culture Collection or ATCC 25923) and rat osteoblast cells (UMR-106) 
were purchased from ATCC (Manassas, VA). 
 
Preparation of osteoblasts with intracellular S. aureus via co-culturing osteoblast-S. 
aureus  
Rat osteoblast cells were seeded at a density of 5×105 osteoblasts/mL and cultured 
in 6-well plates overnight to form a monolayer in DMEM-F12 supplemented with 10% 
FBS and 1% penicillin/streptomycin solution. Fresh S. aureus inoculum was prepared by 
suspending 5 colonies of S. aureus into 5 mL TSB, and incubated at 37oC for 18 h. The 
bacterial suspension was centrifuged (3750 rpm) at 4oC for 15 min, washed once with 
PBS, and its optical density was then adjusted to have S. aureus of 5×108 colony forming 
units/mL (CFU/mL). Rat osteoblasts and S. aureus were then infected as follows (Fig. 1): 
(i) Osteoblast monolayer was first washed twice with PBS.  S. aureus was pelleted, re-
suspended in DMEM-F12 (without FBS and antibiotics), and then added to the osteoblast 
monolayer at a multiplicity of infection (MOI) of 500:1 S. aureus to osteoblasts. 
Osteoblasts and S. aureus were next infected at 37oC in 5% CO2 humidified incubator for 
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2 h. (ii) The osteoblast monolayer was then washed twice with PBS to remove any non-
adherent bacteria, and cell culture media supplemented with gentamicin (100 μg/mL) was 
added and kept for 2 h to kill remaining extracellular bacteria; gentamicin is an antibiotic 
that is unable to penetrate mammalian cell membranes within short time periods [2, 15, 
16]. Infected osteoblasts were immediately used or kept on ice before being used in the 
rat animal studies. (iii) Samples of infected osteoblasts were lysed using Triton X-100. 
(iv) Cell lysates were cultured on blood agar plates to determine the CFU which 
represents the viable colonies of intracellular S. aureus within osteoblasts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. A schematic diagram describes the process of infecting osteoblasts with 
intracellular S. aureus and confirming that the osteoblasts are infected. (i) Rat osteoblasts 
were infected with S. aureus for 2h. (ii) Extracellular S. aureus were killed with 
gentamicin and washed. (iii) Osteoblasts were lysed using a lysing buffer. (iv) Cell 
lysates were cultured on blood agar plates to count live intracellular S. aureus colonies. 
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Animal groups and open fracture infection procedure 
 
          Sprague-Dawley rats (400-500 g) were obtained from Hilltop Lab Animals 
(Scottdale, PA). All studies were approved by the West Virginia University Institutional 
Animal Care and Use Committee. Our open femur fracture rat model [17, 18] was 
modified and the surgical procedure was described in brief as follows (Fig. 2): After 
sedation of the animals with intraperitoneal anesthetic, the hind leg was shaved prior to 
fracture. A midshaft femur fracture was produced using a custom-made device (Fig. 2A), 
an incision was made to expose the fracture (Fig. 2B), and then the fracture was fixed 
using an intramedullary stainless steel Kirschner wire or K-wire (Fig. 2C). Next, 100 μL 
of treatment solution was gently pipetted into the fracture site without contacting the 
surgical instruments (Fig. 2D). Based on the treatment solutions, rats were randomly 
assigned into the following six groups (six rats per group): 
 
 
 
Group Treatment solution (100 µL) 
Group I PBS 
Group II 106 osteoblasts 
Group III 106 osteoblasts combined with 20 CFU of extracellular S. aureus 
Group IV 106 osteoblasts with *102 CFU intracellular S. aureus 
Group V 106 osteoblasts (infected) with 106 CFU intracellular S. aureus 
Group VI 106 osteoblasts (infected) with 106 CFU intracellular S. aureus combined 
with 20 CFU of extracellular S. aureus 
* This was obtained by diluting the 106 CFU of intracellular S. aureus with non-infected osteoblasts. 
 
 
The incision was subsequently closed (Fig. 2E) and post-operative radiographs were 
taken to verify the fracture fixation. All animals were monitored for the study duration of 
three weeks and euthanized on post-operative day 21. 
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Figure 2. The rat femur was fractured, fixed with a K-wire, and inoculated with 0.1 mL 
solution of PBS, osteoblasts, mixture of osteoblasts and extracellular S. aureus (20 CFU), 
infected osteoblasts with intracellular S. aureus, or mixture of infected osteoblasts and 
extracellular S. aureus (20 CFU). Rats were euthanized on post-operative day 21. (A) 
Creation of a femur fracture using a custom-designed setup. (B) Exposure of the fracture. 
(C) Intramedullary fixation of the fracture using a K-wire. (D) Injection of 0.1 mL 
solution using a pipette. (E) Closure of incision. 
 
 
Microbiological and radiographic evaluations 
 
      On the day of euthanasia, bone and muscle tissues were collected in 15 mL centrifuge 
tubes with 5 mL PBS and homogenized. Samples of bone and muscle homogenates were 
diluted and plated on blood agar plates, and S. aureus colonies were counted after 
incubating the plates, at 37oC for 24h. In addition, K-wires that were used to fix the 
fractured femurs were collected at euthanasia, cut into 2cm-long pieces, rolled on blood 
agar plates and cultured at 37oC for 24 h. Radiographs of fractured femurs were taken on 
post-operative days 0, 7, and 21. 
 
A B C 
D E 
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Body weight and complete blood count 
The body weights of animals were measured on the day of surgery and 
immediately before euthanasia and the net weight gain/loss was calculated. Blood 
samples were collected immediately prior to euthanasia from the heart and analyzed for 
complete blood counts by Antech Diagnostics, Inc. (Southaven, MS). 
 
Statistical analysis  
Values of CFU, body weight gain/loss, and blood cell counts were expressed as 
the mean ± standard deviation. Differences in body weight gain and blood cell counts 
were analyzed using one-way ANOVA. P value ≤ 0.05 was considered statistically 
significant.  JMP (V9) software was used (SAS Institute, Inc., Cary, NC). 
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Results 
 
Intracellular S. aureus causes high bacterial burden in bone and muscle tissues 
          Rats (Groups IV, V, and VI) inoculated with infected osteoblasts (102 or 106 CFU 
of intracellular S. aureus) led to high CFU counts (i.e. ~106 CFU/mL) on post-operative 
day 21 in the bone and muscle samples (Fig. 3A). There were no significant differences 
in CFUs among the animal groups (i.e. Groups IV, V, and VI) inoculated with infected 
osteoblasts on post-operative day 21, although relatively higher CFU counts were found 
in the bone samples compared to the muscle samples of the same animal group. By 
contrast, no bacteria were observed on post-operative day 21 in the rats (i.e. Groups I, II, 
and III) inoculaed with PBS, osteoblasts, and osteoblasts combined with 20 CFU of 
extracellular S. aureus (Fig. 3A). Correspondingly, heavy bacterial growth was seen in 
the blood agar plates rolled with the K-wires from animals inoculated with infected 
osteoblasts (102 or 106 CFU) while no bacterial colonies were found in rolling K-wires 
extracted from animals inoculated with PBS, osteoblasts, and osteoblasts combined with 
20 CFU of extracellular S. aureus (Fig. 3B). Gross observation before euthanasia showed 
pus pockets at the fracture sites in rats inoculated with infected osteoblasts (i.e. Groups 
IV, V, and VI).  No S. aureus growth (data not shown) was observed on post-operative 
day 21 in the blood samples collected from all the animal groups studied. 
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Figure 3 (A) 
 
Figure 3 (B) 
Figure 3. (A) Bone (femur) and muscle tissue homogenates reported high S. aureus 
CFUs in the animal groups inoculated with infected osteoblasts (i.e. Groups IV, V, and 
VI); data were from six rats. No CFU was found in the animal groups inoculated with 
PBS, osteoblasts, and a mixture of osteoblasts and extracellular S. aureus (20 CFU) (i.e. 
Groups I, II, and III). (B) K-wire rolling experiments showed high S. aureus growth in 
the animal groups inoculated with infected osteoblasts; no bacterial growth was observed 
in the animal groups inoculated with PBS, osteoblasts, and a mixture of osteoblasts and 
extracellular S. aureus (20 CFU). 
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Radiographic assessment of bone infection 
No signs of infection were observed on post-operative day 21 in the radiographs 
of rats (i.e. Groups I, II, and III) inoculated with PBS, osteoblasts, and osteoblasts 
combined with 20 CFU of extracellular S. aureus (Fig. 4A); the X-ray images of these 
animals were characterized by the formation of normal bridging calluses at the fracture 
sites. By contrast, animal groups (i.e. Groups IV, V, and VI) inoculated with infected 
osteoblasts (102 or 106 CFU) exhibited severe osteolysis on post-operative day 21.  
Meanwhile, no severe osteolysis was observed on post-operative day 7 in the animals 
inoculated with infected osteoblasts (Fig. 4B). 
 
 
 
 
Figure 4 (A) 
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Figure 4 (B) 
Figure. 4. (A) Radiographs of fractured femurs on post-operative day 21 presented 
significant osteolysis in the animal groups inoculated with infected osteoblasts (i.e. 
Groups IV, V, and VI) while normal bone healing was seen in the animal groups 
inoculated with PBS, osteoblasts, and a mixture of osteoblasts and extracellular S. aureus 
(20 CFU) (i.e. Groups I, II, and III). (B) Radiographs of fractured femurs on post-
operative day 0, 7, and 21 did not show severe osteolysis in the rats inoculated with 
infected osteoblasts (e.g. Group VI) on post-operative day 7. 
 
 
 
Body weight and complete blood counts 
 
A significant loss in body weight was observed in rat groups (i.e. Groups IV, V, 
and VI) inoculated with infected osteoblasts (102 or 106 CFU of intracellular S. aureus) 
compared to the animal groups (i.e. Groups I, II, and III) inoculated with PBS, 
osteoblasts, and osteoblasts combined with 20 CFU of extracellular S. aureus (Fig. 5).  
Interestingly, relatively more, although not significant, weight gain was seen on post-
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operative day 21 in the animal groups (i.e. Groups II and III) inoculated with osteoblasts 
compared to the group (i.e. Group I) inoculated with PBS (Fig. 5).   
 
 
 
 
 
 
 
 
Figure 5.  Net weight loss of the rats on post-operative day 21 was significantly higher in 
the animal groups inoculated with infected osteoblasts (i.e. Groups V, and VI) compared 
to those in the animal groups inoculated with PBS, osteoblasts, and a mixture of 
osteoblasts and extracellular S. aureus (20 CFU) (i.e. Groups I, II, and III). Data were an 
average of six rats in each group. 
 
 
The neutrophils in the blood of rat groups (i.e. Groups IV, V, and VI) inoculated 
with infected osteoblasts (102 or 106 CFU) were significantly elevated on post-operative 
day 21 compared to the animal groups (i.e. Groups I, II, and III) inoculated with PBS, 
osteoblasts, and osteoblasts combined with 20 CFU of extracellular S. aureus (Fig. 6).  
No significant differences (data not shown) were seen on post-operative day 21 in the 
numbers of lymphocytes, monocytes, and eosinophils among all the animal groups 
studied. 
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Figure 6. Complete blood counts on post-operative day 21 showed that neutrophil 
numbers were significantly higher in the animal groups inoculated with infected 
osteoblasts (i.e. Groups IV, V, and VI) compared to those animal groups inoculated with 
osteoblasts and a mixture of osteoblasts and extracellular S. aureus (20 CFU) (i.e. Groups 
II and III). 
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Discussion 
S. aureus is a major human pathogen causing significant morbidity and mortality 
in both community- and hospital-acquired infections. Surprisingly, S. aureus is frequently 
successful in overcoming both host defense mechanisms and most antibiotic treatments, 
was found among chronic and recurrent infections, and could be responsible for such 
infections. This bacterium is believed to have developed several means to combat 
conventional antibiotic therapies, among which are its ability to survive for long periods 
of time inside host cells [14]. The purpose of the present study was to examine whether 
intracellular S. aureus contributes to infection in vivo. Effort was taken to completely 
eradicate extracellular S. aureus in the inoculums by treating them with gentamicin; the 
complete killing of extracellular S. aureus was verified in our studies as well as by others 
[15, 16, 19, 20]. Also, gentamicin remaining in the inoculum samples was expected to 
eliminate any extracellular S. aureus that leaked out within the first few hours after 
infection.  
We investigated whether intracellular S. aureus within osteoblasts could induce 
infection in our open femur fracture rat model. An open femur fracture model was used 
because open fractures have high rates of infection and infection recurrence, and a high 
rate of recurrence or relapse of infections was reported in traumatic extremity injuries (8, 
9). We found that animals inoculated with S. aureus infected osteoblasts with 
intracellular S. aureus CFU of 102 (i.e. Group IV) and 106 (i.e. Groups V and VI) all led 
to severe infections. The results were confirmed by culturing bone and muscle specimens 
from the fracture sites and explanted K-wires (Fig. 3) and visualizing via radiography of 
the fractured bones (Fig. 4). Inoculation of intracellular S. aureus of 102 CFU led to the 
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same degree of infection as 106 CFU inoculum, evidenced by approximately the same 
CFU of bone or muscle specimens on post-operative day 21 (Fig. 3). Animals inoculated 
with no bacteria (i.e. Groups I and II) or with 20 CFU of extracellular S. aureus (i.e. 
Group III) did not exhibit infection on post-operative day 21. No systemic infection was 
observed in any of the animal groups investigated because no CFU was found in blood 
samples. These suggest that intracellular S. aureus of as low as 102 CFU within 
osteoblasts induced bone infections in our rat open femur fracture model; the infection 
was localized. 
It was interesting that severe bone infections could be induced by intracellular S. 
aureus within osteoblasts at a low rate of 102 CFU, which was the same quantity of 
inoculum as our previous rat studies where 102 CFU of extracellular S. aureus was 
sufficient to induce bone infections in our open fracture rat model [17, 18, 21]. This 
suggested that not only extracellular but also intracellular S. aureus of as low as 102 CFU 
could induce severe bone infections in open fractures. Note that inoculation of uninfected 
osteoblasts did not have an effect on infection; no CFU was observed in corresponding 
bone, muscle, and K-wire samples (Fig. 3). However, although not significant, increased 
weight gain was observed with injection of uninfected osteoblasts compared to injection 
of PBS (Fig. 5); the reason was unknown. 
Meanwhile, neutrophils were significantly increased on post-operative day 21 in 
the animal groups inoculated with infected osteoblasts. This finding might suggest that 
neutrophils have played a deleterious role in infections induced by S. aureus infected 
osteoblasts. In the literature, neutrophils may have a protective or a deleterious role in S. 
aureus infection. On one hand, neutrophils have long been believed to provide significant 
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host defense against S. aureus infection. This is mainly because patients who are 
neutropenic or who have defects in neutrophil functions are more susceptible to S. aureus 
infection, and total ablation of neutrophils in an experimental mouse model of S. aureus-
induced septic arthritis led to decreased survival of the animals and increased bacteremia 
[22]. On the other hand, increased neutrophils were also found to correlate with 
decreased survival of mice and increased bacterial burden at the infection site [23, 24]. 
It is important to note that both in vitro and in vivo studies have shown that S. 
aureus can internalize and survive within both phagocytic and non-phagocytic cells. In 
vitro, S. aureus can invade and survive within polymorphonuclear neutrophils and 
monocytes [25-27] and osteoblasts [28, 29]. Infected human osteoblasts were shown to 
release viable S. aureus, which were able to re-infect new osteoblasts [28]. S. aureus can 
also internalize and perhaps even replicate within bovine mammary epithelial cells, both 
in cell lines and in primary culture [30, 31]. In vivo, intracellular S. aureus was found, in 
limited cases, in animals and patients. In animal studies, S. aureus was found to be able to 
internalize and survive in osteoblasts in chick embryos [32] and in bovine alveolar cells 
isolated from milk of infected cows [33]. In patient studies, intracellular S. aureus was 
found inside epithelium, glandular, and myofibroblastic cells in intranasal biopsy 
specimens obtained, during infection symptom-free periods, in three patients with 
recurrent rhinosinusitis [34]. Molecular typing proved the clonal relationship of the 
patient-specific Staphylococci. Intracellular S. aureus was also found in surgical bone 
specimens from a patient who had chronic and recurrent bone infection [35]. The 
intracellular S. aureus appeared to be sequestered and protected from the host immune 
system within the osteoblast or osteocyte cytoplasm for years [35]. In another case, 
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intracellular S. aureus was cultured from five patients with persistent and recurrent 
infections [36]. Alarmingly, some of those intracellular S. aureus were small-colony 
variants which were non-hemolytic and non-pigmented, grew very slowly on routine 
culture media, and were resistant to aminoglycosides under routine conditions. 
Therefore, there is some in vitro and in vivo evidence supporting the potential role 
of intracellular S. aureus in Staphylococci pathogenesis. However, there is no definitive 
in vivo proof before this study showing that intracellular S. aureus is directly responsible 
for or contributes to infections (e.g. chronic and recurrent infection).  The results 
presented here are important because they have demonstrated, for the first time, that 
intracellular S. aureus could induce infection in vivo. Bacteria (e.g. S. aureus) could 
internalize and survive within host cells (e.g. osteoblast) and, after “hiding” for some 
time period (could be up to years [35]), these quiescent bacteria could escape from the 
infected host cells into the surrounding tissue and could be sufficient to initiate a 
recurrence of symptomatic infection.  
Taken together, the findings reported here present the first in vivo direct evidence 
that intracellular S. aureus can induce bone infections and may be responsible for chronic 
and recurrent infections. These findings also suggested that as low as 102 CFU of 
intracellular S. aureus may induce severe bone infections in open fractures. These 
findings may greatly advance our understanding of the pathogenesis of bone infections, 
especially chronic and recurrent infections. The induction of bone infections by 
intracellular S. aureus was studied in this work; however, the findings are expected to be 
applicable to other infections/diseases and intracellular pathogens. 
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CHAPTER 4 
 
Effect of Interleukin 12 on the Killing of Intracellular Staphylococcus 
aureus 
 
 
Abstract 
 
The proinflammatory cytokine IL-12 may play a critical role in host defense 
against intracellular pathogens, including bacteria, viruses, and parasites. We have 
previously demonstrated the ability of intracellular S. aureus to live inside macrophages, 
which may explain the chronic and recurrent nature of Staphylococcal infections. The 
aim of this study was to determine the effect of IL-12 on killing intracellular S. aureus by 
macrophages. Splenic macrophages were isolated from rat spleens, infected, and treated 
with IL-12 or IL-12 neutralized with anti-IL-12 antibody or without IL-12. IL-12 
treatment was found to exhibit a dose-dependent relationship with intracellular S. aureus, 
and resulted in significant reduction of intracellular S. aureus at IL-12 dosages of 250 and 
2500 pg/mL. The enhancement of macrophage killing activity was most effective and 
significant at post-infection 24 - 36 h. Meanwhile, significantly higher levels of IFN-γ 
and IL-12 were released from infected macrophages treated with IL-12 compared to un-
treated cells. No significant changes in reactive oxygen species production were detected 
between treated and un-treated macrophages at post-infection time 0 and 24 h. These 
findings demonstrate that IL-12 can stimulate macrophages to be more potent in killing 
intracellular S. aureus and could be an effective immunotherapeutic agent for preventing 
and treating intracellular Staphylococcal infections. 
Keywords: Intracellular pathogens, Interleukin 12, S. aureus, macrophages, cytokine 
therapy.  
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Introduction  
 
Intracellular pathogens are known to be a strong inducer of type-1 immune 
responses, which are characterized by the robust production of interleukin 12 (IL-12) 
from innate phagocytes and interferon gamma (IFN-γ) from natural killer (NK) cells and 
T-cells. Studies have shown that macrophages failed to be activated to kill intracellular 
bacteria in mice treated with IL-12 or IFN-γ neutralizing antibodies [1-6].  
IL-12 is produced mainly by antigen-presenting cells and acts to connect the 
innate and acquired immunities by inducing differentiation of antigen-specific T-cells of 
Th1 phenotype and the release of IFN-γ from activated T-cells and NK cells [7-10]. IFN-
γ is produced by T-cells and considered to play an important role in activating 
macrophages, the ultimate effector cells in host defense against intracellular infection 
[11, 12]. Studies have reported that macrophages can be competent cells regarding the 
ability to respond to IL-12, which has led to the notion that this cytokine can induce 
macrophage activation through an autocrine pathway [15, 16]. It has been shown that 
macrophages express β1 and β2 chains from the IL-12 receptor (IL-12R) [16]. IL-12 has 
also been involved in programming the macrophage response to lipopolysaccharide (LPS) 
by up-regulating the production of TNF-α [17].  
In this study, we investigated the effects of IL-12 on the bacterial killing capacity 
of macrophages with intracellular S. aureus, and presented evidence to support the 
antibacterial activity of IL-12 against intracellular S. aureus. The findings will extend our 
understanding of the effects of IL-12 on macrophages and may offer insights into an 
immunotherapeutic approach to control chronic and recurrent S. aureus infection. 
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Materials and Methods 
 
Reagents  
Tryptic soy agar (TSA, w/5% sheep blood) plates, tryptic soy broth (TSB), 
phosphate buffered saline (PBS), fetal bovine serum (FBS), 45% glucose solution, 7.5% 
sodium bicarbonate, sodium pyruvate, and Tris-buffer were all obtained from Fisher 
Scientific (Pittsburgh, PA). RPMI-1640 media were purchased from LONZA 
(Walkersville, MD). 100 U/mL penicillin/100 mg/mL streptomycin solution, rat IL-12 
p70 ELISA kit, rat IFN-γ ELISA kit, and recombinant rat IL-12 (IL-12) were from 
Invitrogen (Carlsbad, CA). Gentamicin, Triton X-100, lysostaphin, and ammonium 
chloride were obtained from Sigma (St. Louis, MO). Dichlorofluorescin diacetate 
(H2DCF-DA) was from Life Technologies (Grand Island, NY). Rat anti-IL-12 antibody 
was purchased from R & D Systems (Minneapolis, MN).  
 
IL-12 bioactivity 
 The bioactivity of recombinant rat IL-12 used in this study was assessed based on 
the ability of IL-12 to induce secretion of IFN-γ by macrophages. In brief, splenic 
macrophages of (0.5-1)×107 cells/mL were cultured in a 96-well plate (Fisher Scientific, 
Pittsburgh, PA) in RPMI-1640 supplemented with different doses (0, 1, 10, 100, and 
1000 pg/mL) of recombinant rat IL-12 at 37oC in a 5% CO2 incubator. After 48 h of 
culturing, the supernatant was collected for IFN-γ analysis using enzyme-linked 
immunosorbent assay (ELISA) by measuring the optical density at 450 nm following the 
manufacturer’s guidelines. IFN-γ levels were determined by comparison with a standard 
curve. The results were expressed as mean ± SE and are presented in Figure 1, which 
shows that the recombinant rat IL-12 studied was bioactive. 
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Bacterial culture 
 S. aureus (ATCC 25923) obtained from the American Type Culture Collection 
(ATCC, Manassas, VA). A fresh inoculum was prepared by suspending 5 colonies of S. 
aureus, grown on a blood agar plate, in 5 mL TSB and incubating at 37oC for 18 h. After 
incubation, the S. aureus inoculum was centrifuged at 3750 rpm for 15 min at 4oC and 
washed once with 10 mL PBS to obtain (6-8)×108 colony forming units/mL or CFU/mL. 
The bacteria pellet was then re-suspended in RPMI-1640 medium free from 
streptomycin/penicillin and FBS.  
 
Splenic macrophage isolation and culture 
 Splenic macrophages were obtained as described in (Figure 2). Spleens were 
obtained from healthy adult Sprague Dawley rats, and cut into small pieces in a petri-dish, 
and minced between the frosted ends of microscopic slides. The splenocyte suspension 
was filtered through a 70 μm nylon cell strainer (Fisher Scientific), and centrifuged at 
2500 rpm at 4oC for 5 min. The supernatant was subsequently aspirated and the red blood 
cells were lysed with a 5 mL lysis buffer containing 0.17 M tris-buffer and 0.16 M 
ammonium chloride for 10 min. The lysis process was stopped by adding RPMI-1640 
media supplemented with penicillin/streptomycin, FBS, glucose, sodium bicarbonate, and 
sodium pyruvate (this will be referred to as complete media). The splenocyte suspension 
was then centrifuged again at 2500 rpm at 4oC for 5 min followed by aspiration of the 
supernatant. The splenocyte pellet was washed once with complete RPMI-1640 media by 
centrifugation then re-suspended in complete RPMI-1640 media to obtain (0.5-1)×107 
cells/mL. Cell viability was determined by trypan-blue exclusion assay. Splenocytes were 
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seeded in 48-well plate (Fisher Scientific) for 4 h and non-adherent cells (mainly B and 
T-cells) were washed twice with PBS and adherent cells (primarily macrophages, and 
referred to as splenic macrophages here) were further cultured in complete RPMI-1640 
media and incubated in a 5% CO2 incubator at 37
oC for 48 h.  
 
 
Figure 2. Steps for isolating splenic macrophages. (I) Rat spleens were collected in 
RPMI-1640 complete media. (II) Spleens were cut into small pieces in petri-dish and 
minced between the frosted ends of microscope glass slides to make a single cell 
suspension. (III) and (IV) The cell suspension was filtered through a 70 μm cell strainer. 
(V) Cells were collected by centrifugation at 2500 rpm and 4oC for 5 min. (VI) Cell 
pellet was washed once with RPMI-1640 complete media and the pellet was obtained by 
centrifugation. (VII) Red blood cells in the cell pellet were lysed with Tris-ammonium 
chloride for 10 min and the lysis step was stopped by adding RPMI-1640 complete media. 
(VIII) Cells were re-suspended in RPMI-1640 complete media for further culture. 
 
 
 
Splenic macrophage infection and IL-12 treatment 
Splenic macrophages of (0.5-1)×107 cells/mL were washed 3 times with PBS, 
cultured with S. aureus at a multiplicity of infection (MOI) of 10:1 for 2 h, washed, and 
incubated with gentamicin (100 μg/mL) for 2 h. The infected splenic macrophages were 
first treated with different doses of recombinant rat IL-12 (0, 0.25, 2.5, 25, 250, and 2500 
1 2 3 4 
5 6 7 8 
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pg/mL) in RPMI-1640 media supplemented with 5 μg/mL lysostaphin and 5% FBS for 
24 h. The splenic macrophages were washed and lysed to determine the number of live 
intracellular S. aureus by plating the lysates on blood agar plates. Next, the infected 
splenic macrophages were treated with 250 pg/mL of IL-12 for different time periods (0, 
12, 24, 36, and 48 h). The cell culture supernatants were collected for IFN-γ and IL-12 
quantification using ELISA kits following the manufacturer’s guidelines; duplicates were 
collected for each sample. The splenic macrophages were washed and lysed to determine 
the number of live intracellular S. aureus. Data were presented as mean ± SE from at 
least 3 different trials.  
 
 
 
 
 
 
 
 
 
Figure 1. Quantitative measurement of bioactivity of IL-12 studied. 
 
IL-12 action specificity 
 In order to further confirm the role of IL-12 treatment on infected splenic 
macrophages, IL-12 was pre-treated with anti-IL-12 antibody and then added to infected 
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splenic macrophages. As described in Chart 1, splenic macrophages of (0.5-1)×107 
cells/mL were cultured, infected at an MOI of 10:1 for 2 h, incubated with gentamicin, 
and washed. IL-12 of 250 pg/mL was neutralized with 0.1 μg/mL rat anti-IL-12 antibody 
for 1 h at 37 C, and subsequently added to infected splenic macrophages and incubated 
for 24 h. For comparison, infected splenic macrophages were also treated with or without 
IL-12 of 250 pg/mL for 24 h. The cell culture supernatants were collected to determine 
IFN-γ levels using an ELISA kit; duplicates were collected for each sample. The infected 
splenic macrophages were washed with PBS and lysed to determine the number of 
intracellular S. aureus.  
 
Chart 1. A flowchart for testing IL-12 specificity by adding anti-IL-12 antibody (0.1 
μg/mL) to neutralize IL-12 (250 pg/mL) biological activity for 1 h at 37oC.    
 
 
Reactive oxygen species detection 
Infected or non-infected splenic macrophages of (0.5-1)×107 cells/mL were 
treated either with or without recombinant rat IL-12. At post-infection time 0 and 24 h, 
cells were washed once with PBS and incubated with H2DCF-DA at 37 C for 1 h in the 
dark. The fluorescence intensity was measured using a fluorescent microplate reader 
(BioTek Instrument, Inc., Winooski, VT) at 492 nm/520 nm for 2',7'-dichlorofluorescein 
(DCF), converted intracellularly from H2DCF-DA. The H2DCF-DA fluorescent probe is 
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commonly used to detect reactive oxygen species. Data were average of six samples per 
treatment.  
 
Statistical analysis 
All data were presented as means ± SE. Statistical significance was set at p < 0.05. 
Statistical analysis was performed using GraphPad InStat Version 3.0 (GraphPad 
Software Inco, La Jolla, CA).  
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Results 
 
 
Effect of IL-12 treatment on the survival of S. aureus within infected splenic macrophages 
 The S. aureus CFU within infected splenic macrophages decreased with 
increasing IL-12 concentration in the range of 0-250 pg/mL, and was significantly lower 
at IL-12 of 250 and 2500 pg/mL compared to the control (i.e. without IL-12 treatment) 
(Figure 3A). The intracellular S. aureus CFU within infected splenic macrophages that 
were treated with 250 and 2500 pg/mL of IL-12 was 18- and 14- fold lower than that of 
the control, respectively. Meanwhile, the S. aureus CFU splenic macrophages also 
decreased with increasing treatment time. The S. aureus CFU within splenic 
macrophages that were treated with 250 pg/mL of IL-12 was significantly lower at 24 and 
36 h compared to the corresponding controls without IL-12 treatment (Figure 3B). 
 
 
 
 
 
 
 
 
 
 
Figure 3 (A). Intracellular S. aureus of infected splenic macrophages that were treated 
with recombinant rat IL-12 at different doses (0, 0.25, 2.5, 25, 250, and 2500 pg/mL) for 
24 h. 
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After blocking the activity of IL-12 using anti-IL-12, no significant differences 
were observed in intracellular S. aureus CFU between infected splenic macrophages 
without IL-12 treatment and splenic macrophages treated with antibody pre-treated IL-12 
(Figure 3C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 (B). Intracellular S. aureus of infected splenic macrophages that were treated 
with or without recombinant rat IL-12 of 250 pg/mL for different time periods (0, 12, 24, 
and 36 h). 
 
 
 
Effect of IL-12 treatment on cytokine production in infected splenic macrophages 
  
Compared to cells without IL-12 treatment, infected splenic macrophages treated 
with IL-12 had significantly higher IL-12 production at the post-infection times (i.e. 12, 
24, 36, and 48 h) studied (Figure 4A). Similarly, a significant increase in IFN-  
production was observed at the time periods investigated in IL-12 treated infected splenic 
macrophages compared to the controls without IL-12 treatment (Figure 4B). At post-
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infection 24 h, the IL-12 levels in the IL-12 treated cells and the controls were 
approximately 427 and 324 pg/mL, respectively, and the IFN-  levels in the IL-12 treated 
cells and the controls were approximately 810 and 130 pg/mL, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 (C). Comparison of intracellular S. aureus among infected splenic macrophages 
treated with IL-12 (250 pg/mL), IL-12 (250 pg/mL) that was pre-treated with the anti-IL-
12 antibody, and without IL-12 for 24 h. 
 
 
After blocking the activity of IL-12 using the anti-IL-12 antibody, no significant 
differences were observed in IFN-  levels between infected splenic macrophages without 
IL-12 treatment and splenic macrophages treated with anti-IL-12 antibody pre-treated IL-
12 (Figure 4C). 
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Figure 4 (A). IL-12 levels of infected splenic macrophages treated with or without IL-12 
of 250 pg/mL for different time periods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 (B). IFN-γ levels of infected splenic macrophages treated with or without IL-12 
of 250 pg/mL for different time periods. 
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Figure 4 (C). Comparison of IFN-γ levels among infected splenic macrophages treated 
with IL-12 (250 pg/mL), IL-12 (250 pg/mL) that was pre-treated with the anti-IL-12 
antibody, and without IL-12 for 24 h. 
 
 
Effect of IL-12 treatment on reactive oxygen species production in splenic macrophages 
No significant differences in DCF levels were detected between IL-12 treated and 
un-treated splenic macrophages at post-infection time 0 and 24 h (Figure 5). 
 
 
 
 
 
 
 
 
 
Figure 5. DCF levels of infected and non-infected splenic macrophages that were treated 
with or without IL-12 of 250 pg/mL for 24 h. 
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Discussion 
 
Killing of intracellular S. aureus may be critical for effective therapies to treat and 
prevent chronic and recurrent Staphylococcal infections. In vivo, the control of 
intracellular pathogens depends on the activation of Th1 immune responses, suggesting a 
key role for macrophages. The importance of IL-12 production and subsequent IFN-γ 
secretion to control intracellular bacteria has been demonstrated in multiple studies [4, 6, 
19, 20]. However, few studies to date have examined the activity of IL-12 on macrophage 
killing activity in vitro. Herein, we used an in vitro infection model of intracellular S. 
aureus to examine the effect of IL-12 on the killing activity of splenic macrophages 
against intracellular S. aureus.  
We found that the intracellular killing activity of macrophages was enhanced with 
IL-12 treatment, since the intracellular S. aureus CFU decreased with increasing IL-12 
doses. Compared to the control without IL-12 treatment, significant differences were 
observed at 250 and 2500 pg/mL (Figure 3A); and the best effective time span was found 
to be between post-infection 24-36 h (Figure 3B). The enhancement of macrophage 
killing activity by IL-12 treatment was further confirmed by neutralizing IL-12 with an 
antibody specific to rat IL-12 where no significant differences were observed between 
macrophages treated with and without IL-12 neutralized with anti-IL-12 antibody (Figure 
3C). This finding was consistent with the observation that animals challenged with 
bacteria and subsequently receiving treatment with anti-IL-12 antibody presented more 
severe disease symptoms [4, 18]. Similarly, neutralizing IL-12 using the anti-IL-12 
antibody increased morbidity in virus-infected mice compared with un-treated animals 
[24]. By contrast, exogenous IL-12 was able to induce the activities of dendritic cells and 
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cytotoxic T-cells against influenza virus infection when patients’ own antiviral immune 
responses were poor [27, 26]. Exogenous IL-12 also rescued mice that were challenged 
with a lethal dose of encephalomyocarditis virus through IFN-γ-mediated responses [25]. 
As a result, Orange and Coutelier suggested that low doses of IL-12 combined with 
dendritic cells may be used as a potential immunotherapeutic approach against viral 
infections [28, 29]. 
We further found that the enhancement of macrophage killing activity was 
associated with the production of IL-12 and IFN- . Significantly higher levels of IL-12 
and IFN-  were detected in infected macrophages treated with IL-12 compared to 
controls without IL-12 treatment (Figures 4A and 4B) while no significant differences 
were observed in IFN-  levels between macrophages treated with and without IL-12 that 
was neutralized with anti-IL-12 antibody (Figure 4C). It was clear that exogenous IL-12 
treatment resulted in significantly higher production of IFN-  and IL-12 within infected 
macrophages, which may reflect the notion that IL-12 could induce macrophage 
activation through an autocrine pathway [15, 16]. Both IL-12 and IFN-γ were previously 
found to be required for activating immune cells like macrophages during parasitic 
infections, such as Leishmania major [30], by inducing Th1 differentiation and activating 
macrophages to produce nitrogen oxide [31-33]. IL-12 also plays a critical role during the 
early stages of viral infection by inducing NK cell cytotoxicity and IFN-γ production, 
which leads to improved antimicrobial activity of phagocytic cells [27, 34-36].  
 Oxidative burst is one of the defense mechanisms used against pathogens, and 
macrophages activated by IFN-γ were found to have increased release of nitric oxide 
(NO) and reactive oxygen species (ROS) and enhanced bactericidal activities [13, 14]. 
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However, some bacteria such as Brucella, Salmonella, and Shigella can avoid inducing 
oxidative burst when they encounter host cells (21, 22), and some bacteria like S. aureus 
may express enzymes that can scavenge ROS species including O2
- (23).  In this study, no 
significant differences in ROS levels were observed between macrophages treated with 
and without IL-12 at post-infection time 0 and 24 h (Figure 5). This observation may 
suggest an alternative killing activity than oxidative burst. 
 
Conclusions 
 
In this study, we examined the effect of IL-12 treatment on macrophage killing 
activity in vitro by assessing the viable intracellular bacteria and cytokine as well as 
reactive oxygen species production in infected splenic macrophages. We found that IL-12 
treatment could significantly enhance the in vitro killing activity of macrophages and the 
enhancement was dose and time dependent. Moreover, IL-12 treatment led to a 
significant increase in IFN-  and IL-12 production with no significant changes in ROS 
production in infected macrophages compared to cells without IL-12 treatment. The 
enhancement of macrophage killing activity by IL-12 was abolished when IL-12 was pre-
treated with the anti-IL-12 antibody.   
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CHAPTER 5 
 
General Discussion 
 
 
Although S. aureus has been primarily considered an extracellular pathogen, it is 
now clear that it can be internalized by both phagocytes and non-phagocytic cells. 
Intracellular S. aureus is considered to play an important role in their persistence (host 
defenses evasion) and recurrence (antibiotic failure) of infection.  
The goal of my dissertation was to understand the invasion of S. aureus in 
macrophages and osteoblasts and to explore potential prophylactic and therapeutic 
interventions. The in vitro infection models demonstrate direct evidence for the ability of 
S. aureus to be internalized by both phagocytic and non-phagocytic cells. Osteoblasts are 
the most important cells for bone formation; therefore, any damage occurring to these 
cells may result in disrupted bone homeostasis. Macrophages, on the other hand, are 
important immune cells against invading pathogens and need to be fully efficient in 
clearing bacteria in a short period of time. Our data have shown that S. aureus could 
survive for several days within osteoblasts and macrophages, in the presence of 
antibiotics. This time may be sufficient to induce phenotypic and genotypic changes in 
the intracellular S. aureus which may make it harder to clear.     
The success of the in vitro infection models has led us to examine the potential 
that intracellular S. aureus alone could induce infection in an animal model. By 
inoculating S. aureus infected osteoblasts, we found that intracellular S. aureus 
inoculation of as low as 102 CFUs could induce severe bone infections in an open femur 
fracture rat model. 
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The role of IL-12 in intracellular pathogens’ clearance can be multifaceted. It is 
well established that IL-12 stimulates IFN-γ in T-cells and NK cells. Also, IL-12 induces 
CD4 Th cell differentiation toward a Th1 subset, and could have indirect, but more 
widespread, effects within bone tissue. Our data have shown that IL-12 treatment has led 
to a significant upgrade of IFN-  production by infected macrophages and resulted in 
significant reduction of intracellular S. aureus. As a result, IL-12 may be an innovative 
therapeutic agent for eliminating intracellular S. aureus surviving within host cells. 
 
Future Studies 
 According to the publication report from Web of Knowledge, there are very few 
publications studying the pathogenesis of S. aureus infection in an in vitro co-culture 
system which involves both osteoblasts and macrophages. Our data from Chapter 4 
gives a promising future for IL-12 treatment in the presence of antibiotics to eliminate 
intracellular S. aureus infection; therefore, studying the effect of IL-12 in a system where 
both cell types (osteoblasts and macrophages) are present will provide a better model of 
the actual situation.  
Although our in vivo model is the first proof to directly link of the contribution of 
intracellular S. aureus to cause bone infection; however, antibiotics were dismissed from 
this model. In any clinical case of implant-associated infection, patients are treated with 
antibiotics for at least 6 weeks following the surgery. A better model should be designed 
to introduce antibiotics during the animal infection time to eliminate extracellular S. 
aureus that leaks out from osteoblasts in the first several days.  
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- Hamza T, Li B.  Poster presentation.  Self-assembly multifunctional 
nanocoatings for biomedical applications. Multifunctional Nanomaterials 
International Symposium, Roanoke, WV, April 2008. (1st place award) 
- Ogle H, Hamza T, Li B. Poster Presentation. Antibiotic-eluting nanotechnology 
coatings for potential prevention of device-associated infections. WV 
Undergraduate Research Day at the Capitol, Charleston, WV, January 2008. 
 
Professional Experience 
 
- Organizing School of Pharmacy Research Day………………...……………. 2010 
- Teaching Arabic As A Second Language……………………………….2007-2010 
 
Membership in Professional Organizations 
 
- American Association of Pharmaceutical Scientists 
- Orthopaedic Research Society 
- The Association of Medical Laboratory Immunologists (AMLI) 
- Microbiology Group Members 
 
Personal Strengths and Skills 
 
 Achiever, Inducer, Positive, Restorative, and Social  
 
 
